| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Lymphocytic, Chronic, B-Cell | 75 | 2023 | 1646 | 4.010 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 62 | 2024 | 1560 | 3.600 |
Why?
|
| Leukemia, Myeloid, Acute | 52 | 2025 | 3645 | 2.460 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 115 | 2024 | 11868 | 2.220 |
Why?
|
| Hodgkin Disease | 37 | 2020 | 1383 | 2.060 |
Why?
|
| Myelodysplastic Syndromes | 33 | 2024 | 1403 | 2.030 |
Why?
|
| Asparaginase | 21 | 2024 | 240 | 1.620 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 28 | 2024 | 1434 | 1.570 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 16 | 2023 | 385 | 1.460 |
Why?
|
| Mutation | 91 | 2024 | 30196 | 1.350 |
Why?
|
| Gene Expression Regulation, Leukemic | 25 | 2021 | 657 | 1.220 |
Why?
|
| Doxorubicin | 46 | 2024 | 2230 | 1.190 |
Why?
|
| Cancer Vaccines | 22 | 2024 | 1044 | 1.100 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 37 | 2024 | 5753 | 1.070 |
Why?
|
| Bone Marrow Transplantation | 45 | 2023 | 2729 | 1.040 |
Why?
|
| Venous Thromboembolism | 16 | 2024 | 1882 | 1.000 |
Why?
|
| Lymphoma, Non-Hodgkin | 27 | 2023 | 1376 | 0.960 |
Why?
|
| Prednisone | 26 | 2024 | 1565 | 0.910 |
Why?
|
| Vincristine | 31 | 2024 | 1039 | 0.890 |
Why?
|
| Anemia, Sickle Cell | 12 | 2024 | 1067 | 0.870 |
Why?
|
| Cyclophosphamide | 36 | 2024 | 2228 | 0.850 |
Why?
|
| Lymphoma, Follicular | 17 | 2016 | 459 | 0.830 |
Why?
|
| Proto-Oncogene Proteins c-myc | 13 | 2021 | 995 | 0.830 |
Why?
|
| Antigens, Neoplasm | 20 | 2022 | 2002 | 0.820 |
Why?
|
| Remission Induction | 44 | 2024 | 2411 | 0.810 |
Why?
|
| Sickle Cell Trait | 2 | 2021 | 86 | 0.810 |
Why?
|
| Disease-Free Survival | 66 | 2024 | 6832 | 0.790 |
Why?
|
| Sulfonamides | 10 | 2024 | 1984 | 0.780 |
Why?
|
| Humans | 614 | 2025 | 765956 | 0.770 |
Why?
|
| Chromosome Aberrations | 21 | 2021 | 1774 | 0.760 |
Why?
|
| Myeloproliferative Disorders | 8 | 2022 | 616 | 0.760 |
Why?
|
| Proto-Oncogene Proteins | 28 | 2024 | 4520 | 0.730 |
Why?
|
| B-Lymphocytes | 29 | 2023 | 4778 | 0.730 |
Why?
|
| Cytarabine | 19 | 2024 | 698 | 0.660 |
Why?
|
| Neoplasm Proteins | 21 | 2021 | 3596 | 0.660 |
Why?
|
| CD8-Positive T-Lymphocytes | 21 | 2024 | 4642 | 0.660 |
Why?
|
| Neoplasm Recurrence, Local | 29 | 2023 | 9373 | 0.650 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 17 | 2018 | 891 | 0.650 |
Why?
|
| Neoplasm, Residual | 14 | 2020 | 1009 | 0.640 |
Why?
|
| Lymphoma, B-Cell | 19 | 2019 | 943 | 0.640 |
Why?
|
| Leukemia | 12 | 2024 | 1522 | 0.640 |
Why?
|
| Hematopoiesis | 17 | 2023 | 2058 | 0.630 |
Why?
|
| Anticoagulants | 19 | 2023 | 4862 | 0.620 |
Why?
|
| Antineoplastic Agents | 45 | 2021 | 13648 | 0.620 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 13 | 2017 | 689 | 0.610 |
Why?
|
| Female | 374 | 2025 | 396101 | 0.610 |
Why?
|
| Neoplasms, Second Primary | 16 | 2024 | 1050 | 0.610 |
Why?
|
| Male | 338 | 2025 | 363691 | 0.600 |
Why?
|
| Vinblastine | 7 | 2019 | 483 | 0.600 |
Why?
|
| Hematologic Neoplasms | 12 | 2024 | 1927 | 0.590 |
Why?
|
| Tumor Suppressor Protein p53 | 15 | 2024 | 2942 | 0.590 |
Why?
|
| Antibiotics, Antineoplastic | 8 | 2023 | 679 | 0.590 |
Why?
|
| Survival Rate | 64 | 2024 | 12795 | 0.580 |
Why?
|
| Middle Aged | 273 | 2025 | 223004 | 0.580 |
Why?
|
| Prognosis | 94 | 2024 | 29921 | 0.570 |
Why?
|
| Anemia | 5 | 2023 | 1511 | 0.570 |
Why?
|
| Adult | 271 | 2024 | 223038 | 0.570 |
Why?
|
| Neoplasms | 39 | 2024 | 22340 | 0.560 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 15 | 2017 | 691 | 0.560 |
Why?
|
| Gene Expression Profiling | 42 | 2024 | 9524 | 0.550 |
Why?
|
| Gene Expression Regulation, Neoplastic | 32 | 2021 | 8611 | 0.550 |
Why?
|
| Osteonecrosis | 5 | 2019 | 230 | 0.530 |
Why?
|
| Aged | 205 | 2024 | 171114 | 0.530 |
Why?
|
| Lymphoma | 10 | 2023 | 1897 | 0.520 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 7 | 2018 | 230 | 0.510 |
Why?
|
| Polymorphism, Genetic | 18 | 2013 | 4247 | 0.510 |
Why?
|
| T-Lymphocytes | 28 | 2024 | 10261 | 0.500 |
Why?
|
| Vidarabine | 8 | 2015 | 343 | 0.500 |
Why?
|
| Dioxygenases | 6 | 2024 | 354 | 0.500 |
Why?
|
| Graft vs Host Disease | 16 | 2024 | 3078 | 0.500 |
Why?
|
| Transplantation, Homologous | 28 | 2024 | 4860 | 0.490 |
Why?
|
| CD4-Positive T-Lymphocytes | 13 | 2022 | 4405 | 0.480 |
Why?
|
| Plateletpheresis | 3 | 2019 | 39 | 0.480 |
Why?
|
| Immunotherapy, Adoptive | 7 | 2024 | 1510 | 0.480 |
Why?
|
| Pyrimidines | 16 | 2019 | 3047 | 0.470 |
Why?
|
| Drug Resistance, Neoplasm | 20 | 2021 | 5337 | 0.470 |
Why?
|
| Apoptosis | 33 | 2021 | 9514 | 0.450 |
Why?
|
| DNA-Binding Proteins | 26 | 2024 | 9601 | 0.450 |
Why?
|
| Methotrexate | 9 | 2018 | 1722 | 0.450 |
Why?
|
| DNA Copy Number Variations | 13 | 2021 | 2045 | 0.450 |
Why?
|
| Zebrafish | 21 | 2018 | 3035 | 0.440 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 11 | 2023 | 497 | 0.440 |
Why?
|
| Burkitt Lymphoma | 6 | 2016 | 338 | 0.430 |
Why?
|
| Stem Cell Transplantation | 8 | 2021 | 1602 | 0.430 |
Why?
|
| Progeria | 5 | 2013 | 182 | 0.430 |
Why?
|
| Treatment Outcome | 116 | 2024 | 65189 | 0.430 |
Why?
|
| Aged, 80 and over | 97 | 2024 | 59488 | 0.430 |
Why?
|
| Genomic Instability | 5 | 2021 | 718 | 0.430 |
Why?
|
| Receptors, Antigen, B-Cell | 8 | 2023 | 545 | 0.430 |
Why?
|
| Thrombosis | 8 | 2023 | 2949 | 0.420 |
Why?
|
| In Situ Hybridization, Fluorescence | 11 | 2016 | 2505 | 0.420 |
Why?
|
| Lymphocyte Transfusion | 8 | 2021 | 236 | 0.420 |
Why?
|
| Leukemia, Myeloid | 8 | 2021 | 696 | 0.410 |
Why?
|
| Adolescent | 115 | 2024 | 88832 | 0.400 |
Why?
|
| Survival Analysis | 47 | 2020 | 10070 | 0.400 |
Why?
|
| Enoxaparin | 5 | 2020 | 390 | 0.400 |
Why?
|
| Lymphopenia | 3 | 2019 | 297 | 0.400 |
Why?
|
| Chromosomes, Human, Pair 9 | 6 | 2020 | 533 | 0.400 |
Why?
|
| Transplantation, Autologous | 34 | 2020 | 2120 | 0.390 |
Why?
|
| Child, Preschool | 79 | 2024 | 42500 | 0.390 |
Why?
|
| Tumor Microenvironment | 9 | 2025 | 3946 | 0.390 |
Why?
|
| Bone Marrow | 16 | 2025 | 2921 | 0.390 |
Why?
|
| DNA, Mitochondrial | 3 | 2024 | 869 | 0.390 |
Why?
|
| Melanoma | 15 | 2022 | 5719 | 0.380 |
Why?
|
| Aminoglycosides | 1 | 2012 | 161 | 0.380 |
Why?
|
| Cell Line, Tumor | 34 | 2024 | 17075 | 0.380 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 13 | 2024 | 1410 | 0.380 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2013 | 166 | 0.380 |
Why?
|
| Cell Transformation, Neoplastic | 15 | 2018 | 2844 | 0.370 |
Why?
|
| Ikaros Transcription Factor | 4 | 2021 | 230 | 0.360 |
Why?
|
| Child | 99 | 2024 | 80563 | 0.350 |
Why?
|
| Janus Kinase 2 | 6 | 2024 | 562 | 0.350 |
Why?
|
| Anthracyclines | 3 | 2023 | 284 | 0.350 |
Why?
|
| Intracranial Hemorrhages | 5 | 2023 | 814 | 0.350 |
Why?
|
| Leukemia, Promyelocytic, Acute | 5 | 2013 | 249 | 0.340 |
Why?
|
| Hematopoietic Stem Cells | 16 | 2021 | 3401 | 0.340 |
Why?
|
| Reed-Sternberg Cells | 4 | 2018 | 78 | 0.340 |
Why?
|
| Chromosome Deletion | 8 | 2020 | 1385 | 0.340 |
Why?
|
| Neuroblastoma | 7 | 2017 | 1263 | 0.340 |
Why?
|
| Disease Progression | 31 | 2020 | 13631 | 0.330 |
Why?
|
| Aging | 6 | 2023 | 8731 | 0.330 |
Why?
|
| Polyethylene Glycols | 6 | 2021 | 1188 | 0.330 |
Why?
|
| Protein Disulfide-Isomerases | 3 | 2019 | 209 | 0.320 |
Why?
|
| Protein-Tyrosine Kinases | 8 | 2019 | 2423 | 0.320 |
Why?
|
| Genes, p53 | 7 | 2017 | 711 | 0.320 |
Why?
|
| Transplantation Conditioning | 11 | 2022 | 1635 | 0.320 |
Why?
|
| Razoxane | 5 | 2012 | 43 | 0.320 |
Why?
|
| DNA Methylation | 15 | 2024 | 4424 | 0.310 |
Why?
|
| Mediastinal Neoplasms | 4 | 2019 | 403 | 0.310 |
Why?
|
| Evolution, Molecular | 6 | 2021 | 1889 | 0.310 |
Why?
|
| Blood Donors | 3 | 2019 | 342 | 0.300 |
Why?
|
| Mice | 64 | 2024 | 81818 | 0.300 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 3 | 2020 | 102 | 0.300 |
Why?
|
| Young Adult | 56 | 2024 | 59886 | 0.300 |
Why?
|
| Signal Transduction | 30 | 2024 | 23600 | 0.300 |
Why?
|
| Pyrazoles | 8 | 2019 | 2033 | 0.300 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 15 | 2022 | 5389 | 0.290 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 5 | 2007 | 166 | 0.290 |
Why?
|
| Animals | 91 | 2024 | 168759 | 0.290 |
Why?
|
| Follow-Up Studies | 55 | 2023 | 39194 | 0.290 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 6 | 2017 | 350 | 0.290 |
Why?
|
| Oligodeoxyribonucleotides | 3 | 2024 | 705 | 0.290 |
Why?
|
| Phosphoproteins | 5 | 2020 | 2446 | 0.280 |
Why?
|
| Quercetin | 2 | 2019 | 97 | 0.280 |
Why?
|
| Receptor Tyrosine Kinase-like Orphan Receptors | 2 | 2018 | 43 | 0.280 |
Why?
|
| PTEN Phosphohydrolase | 7 | 2020 | 1119 | 0.280 |
Why?
|
| Etoposide | 11 | 2019 | 636 | 0.280 |
Why?
|
| Lung Neoplasms | 22 | 2022 | 13451 | 0.280 |
Why?
|
| Gene Deletion | 7 | 2020 | 2666 | 0.280 |
Why?
|
| Recurrence | 33 | 2023 | 8501 | 0.280 |
Why?
|
| Drug Administration Schedule | 26 | 2019 | 4850 | 0.270 |
Why?
|
| Dexamethasone | 7 | 2018 | 1963 | 0.270 |
Why?
|
| Immunoglobulin Heavy Chains | 11 | 2018 | 648 | 0.270 |
Why?
|
| Cell Proliferation | 20 | 2021 | 10429 | 0.270 |
Why?
|
| Infant | 52 | 2021 | 36385 | 0.270 |
Why?
|
| Nuclear Proteins | 10 | 2024 | 5783 | 0.260 |
Why?
|
| Antigens, CD | 16 | 2011 | 4025 | 0.260 |
Why?
|
| Chromosomes, Human | 3 | 2016 | 437 | 0.260 |
Why?
|
| Clone Cells | 11 | 2021 | 1672 | 0.260 |
Why?
|
| Atherosclerosis | 2 | 2019 | 3425 | 0.260 |
Why?
|
| Polymerase Chain Reaction | 26 | 2016 | 6069 | 0.260 |
Why?
|
| Combined Modality Therapy | 39 | 2020 | 8529 | 0.260 |
Why?
|
| Azepines | 2 | 2019 | 327 | 0.260 |
Why?
|
| Isocitrate Dehydrogenase | 3 | 2024 | 954 | 0.260 |
Why?
|
| Brain Ischemia | 1 | 2019 | 3000 | 0.260 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 3 | 2018 | 169 | 0.260 |
Why?
|
| Thrombocytopenia | 5 | 2023 | 1171 | 0.260 |
Why?
|
| Mitochondria | 9 | 2024 | 3673 | 0.260 |
Why?
|
| DNA, Neoplasm | 6 | 2020 | 1742 | 0.260 |
Why?
|
| Apoptosis Regulatory Proteins | 5 | 2014 | 1151 | 0.250 |
Why?
|
| Heparin, Low-Molecular-Weight | 4 | 2022 | 345 | 0.250 |
Why?
|
| Genetic Linkage | 3 | 2005 | 2341 | 0.250 |
Why?
|
| Immunoglobulins | 5 | 2018 | 852 | 0.250 |
Why?
|
| Polymorphism, Single Nucleotide | 18 | 2021 | 16047 | 0.250 |
Why?
|
| Antigen Presentation | 6 | 2023 | 1250 | 0.250 |
Why?
|
| Chemokine CCL3 | 3 | 2016 | 84 | 0.250 |
Why?
|
| High-Throughput Nucleotide Sequencing | 9 | 2024 | 3655 | 0.250 |
Why?
|
| Neoplasm Staging | 31 | 2019 | 11206 | 0.250 |
Why?
|
| Phosphatidylinositol 3-Kinases | 6 | 2023 | 2878 | 0.250 |
Why?
|
| Retrospective Studies | 61 | 2024 | 81515 | 0.250 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 2310 | 0.240 |
Why?
|
| Transcription, Genetic | 9 | 2021 | 7599 | 0.240 |
Why?
|
| Natural Killer T-Cells | 3 | 2013 | 319 | 0.240 |
Why?
|
| Adenosine A2 Receptor Agonists | 3 | 2019 | 31 | 0.240 |
Why?
|
| Receptor, Notch1 | 4 | 2014 | 517 | 0.240 |
Why?
|
| Whole-Body Irradiation | 8 | 2007 | 438 | 0.240 |
Why?
|
| Piperidines | 8 | 2022 | 1664 | 0.240 |
Why?
|
| Myeloid Cells | 6 | 2018 | 839 | 0.240 |
Why?
|
| Epigenesis, Genetic | 7 | 2022 | 3819 | 0.240 |
Why?
|
| Cardiotonic Agents | 5 | 2016 | 538 | 0.240 |
Why?
|
| Neoplasms, Radiation-Induced | 4 | 2018 | 540 | 0.240 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2016 | 647 | 0.230 |
Why?
|
| Alternative Splicing | 4 | 2019 | 1107 | 0.230 |
Why?
|
| Xenograft Model Antitumor Assays | 9 | 2024 | 3608 | 0.230 |
Why?
|
| Tumor Cells, Cultured | 16 | 2022 | 6113 | 0.230 |
Why?
|
| Immunologic Memory | 5 | 2021 | 1375 | 0.230 |
Why?
|
| Dendritic Cells | 8 | 2024 | 2747 | 0.230 |
Why?
|
| Glutarates | 2 | 2018 | 243 | 0.230 |
Why?
|
| Immunoglobulin Variable Region | 7 | 2022 | 419 | 0.230 |
Why?
|
| Biological Assay | 1 | 2007 | 627 | 0.230 |
Why?
|
| Survivors | 8 | 2016 | 2372 | 0.220 |
Why?
|
| Germ-Line Mutation | 7 | 2018 | 1884 | 0.220 |
Why?
|
| Melanoma, Experimental | 4 | 2020 | 558 | 0.220 |
Why?
|
| Receptors, Antigen, T-Cell | 9 | 2024 | 2570 | 0.220 |
Why?
|
| Immunohistochemistry | 18 | 2016 | 11022 | 0.220 |
Why?
|
| Class Ib Phosphatidylinositol 3-Kinase | 1 | 2024 | 42 | 0.220 |
Why?
|
| Lymphoproliferative Disorders | 4 | 2012 | 526 | 0.220 |
Why?
|
| Hedgehog Proteins | 2 | 2019 | 774 | 0.220 |
Why?
|
| Translocation, Genetic | 13 | 2016 | 1394 | 0.220 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 7 | 2004 | 633 | 0.220 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 17 | 2014 | 3796 | 0.220 |
Why?
|
| Lipopeptides | 1 | 2024 | 72 | 0.220 |
Why?
|
| Fusion Proteins, bcr-abl | 8 | 2014 | 430 | 0.220 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 8 | 2012 | 1624 | 0.220 |
Why?
|
| Erythropoiesis | 3 | 2020 | 691 | 0.210 |
Why?
|
| Germinal Center | 2 | 2020 | 379 | 0.210 |
Why?
|
| p21-Activated Kinases | 1 | 2024 | 127 | 0.210 |
Why?
|
| Immunotherapy | 9 | 2025 | 4752 | 0.210 |
Why?
|
| Antineoplastic Agents, Alkylating | 5 | 2014 | 614 | 0.210 |
Why?
|
| Antigens, CD34 | 7 | 2013 | 656 | 0.210 |
Why?
|
| Pyridines | 5 | 2019 | 2888 | 0.210 |
Why?
|
| Cardiotoxins | 2 | 2013 | 35 | 0.210 |
Why?
|
| Cytidine Deaminase | 2 | 2015 | 250 | 0.210 |
Why?
|
| CCAAT-Enhancer-Binding Protein-alpha | 3 | 2016 | 130 | 0.210 |
Why?
|
| Single-Cell Analysis | 5 | 2024 | 2536 | 0.210 |
Why?
|
| Vaccination | 5 | 2024 | 3426 | 0.210 |
Why?
|
| Mice, Inbred NOD | 9 | 2021 | 1837 | 0.210 |
Why?
|
| Hydroxyurea | 2 | 2022 | 284 | 0.210 |
Why?
|
| Lymphocyte Activation | 8 | 2021 | 5501 | 0.210 |
Why?
|
| Receptor, Adenosine A2A | 2 | 2013 | 127 | 0.200 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 2019 | 457 | 0.200 |
Why?
|
| Peptides | 4 | 2020 | 4331 | 0.200 |
Why?
|
| Protein Kinase Inhibitors | 11 | 2023 | 5696 | 0.200 |
Why?
|
| HLA Antigens | 5 | 2022 | 1339 | 0.200 |
Why?
|
| Treatment Failure | 12 | 2014 | 2652 | 0.200 |
Why?
|
| Antibodies, Neoplasm | 3 | 2010 | 282 | 0.200 |
Why?
|
| Proto-Oncogene Proteins c-akt | 7 | 2014 | 2453 | 0.200 |
Why?
|
| Epstein-Barr Virus Infections | 2 | 2023 | 617 | 0.200 |
Why?
|
| DNA Mutational Analysis | 13 | 2020 | 4108 | 0.200 |
Why?
|
| Neutropenia | 5 | 2023 | 893 | 0.200 |
Why?
|
| Zebrafish Proteins | 3 | 2018 | 1017 | 0.200 |
Why?
|
| Alleles | 17 | 2020 | 6897 | 0.200 |
Why?
|
| Graft vs Leukemia Effect | 4 | 2020 | 122 | 0.190 |
Why?
|
| Cardiovascular Agents | 2 | 2023 | 851 | 0.190 |
Why?
|
| Lymphocyte Depletion | 7 | 2004 | 605 | 0.190 |
Why?
|
| Risk Factors | 48 | 2024 | 74836 | 0.190 |
Why?
|
| Genes, myc | 6 | 2015 | 393 | 0.190 |
Why?
|
| Genomics | 7 | 2022 | 5929 | 0.190 |
Why?
|
| Histocompatibility Antigens Class II | 4 | 2020 | 1441 | 0.190 |
Why?
|
| Sequence Deletion | 4 | 2018 | 1495 | 0.190 |
Why?
|
| Immunosuppressive Agents | 2 | 2013 | 4209 | 0.190 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2023 | 2770 | 0.190 |
Why?
|
| Dacarbazine | 3 | 2019 | 552 | 0.190 |
Why?
|
| Purines | 3 | 2019 | 615 | 0.190 |
Why?
|
| Models, Biological | 8 | 2020 | 9443 | 0.190 |
Why?
|
| Piperazines | 9 | 2016 | 2549 | 0.190 |
Why?
|
| Histone-Lysine N-Methyltransferase | 6 | 2020 | 691 | 0.190 |
Why?
|
| Time Factors | 42 | 2019 | 40065 | 0.190 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2022 | 185 | 0.190 |
Why?
|
| Gene Duplication | 3 | 2014 | 317 | 0.180 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 17 | 2015 | 4562 | 0.180 |
Why?
|
| Brain Neoplasms | 5 | 2023 | 9071 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 14 | 2018 | 6499 | 0.180 |
Why?
|
| Telomerase | 2 | 2021 | 749 | 0.180 |
Why?
|
| Base Sequence | 12 | 2020 | 12403 | 0.180 |
Why?
|
| Antigens, Differentiation | 5 | 2010 | 919 | 0.180 |
Why?
|
| Antigen-Presenting Cells | 6 | 2023 | 962 | 0.180 |
Why?
|
| Up-Regulation | 10 | 2019 | 4137 | 0.180 |
Why?
|
| Genotype | 21 | 2024 | 13024 | 0.180 |
Why?
|
| Heart Diseases | 3 | 2023 | 2821 | 0.180 |
Why?
|
| Gene Expression Regulation | 10 | 2023 | 11888 | 0.180 |
Why?
|
| Adenocarcinoma | 9 | 2017 | 6364 | 0.180 |
Why?
|
| Histiocytes | 1 | 2021 | 95 | 0.180 |
Why?
|
| Bone Marrow Cells | 12 | 2013 | 2412 | 0.180 |
Why?
|
| Enzyme Inhibitors | 7 | 2014 | 3715 | 0.170 |
Why?
|
| Prospective Studies | 38 | 2024 | 54806 | 0.170 |
Why?
|
| Blood Group Antigens | 1 | 2022 | 183 | 0.170 |
Why?
|
| Paclitaxel | 9 | 2022 | 1728 | 0.170 |
Why?
|
| Hypertriglyceridemia | 1 | 2023 | 290 | 0.170 |
Why?
|
| Cell Cycle Proteins | 8 | 2018 | 3430 | 0.170 |
Why?
|
| Haploinsufficiency | 2 | 2013 | 334 | 0.170 |
Why?
|
| Sequence Analysis, DNA | 11 | 2018 | 4772 | 0.170 |
Why?
|
| Membrane Proteins | 5 | 2019 | 7851 | 0.170 |
Why?
|
| Precancerous Conditions | 3 | 2014 | 976 | 0.170 |
Why?
|
| Selection, Genetic | 3 | 2020 | 878 | 0.170 |
Why?
|
| Multiple Myeloma | 7 | 2020 | 5197 | 0.170 |
Why?
|
| Polyomavirus Infections | 1 | 2022 | 194 | 0.170 |
Why?
|
| Dose-Response Relationship, Drug | 17 | 2019 | 10729 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 16 | 2018 | 9249 | 0.170 |
Why?
|
| Oncogene Proteins, Fusion | 9 | 2014 | 1608 | 0.170 |
Why?
|
| Endometrial Neoplasms | 4 | 2014 | 1378 | 0.170 |
Why?
|
| Peyer's Patches | 1 | 2020 | 120 | 0.170 |
Why?
|
| Skin Neoplasms | 5 | 2022 | 5849 | 0.170 |
Why?
|
| Galectin 1 | 2 | 2013 | 128 | 0.170 |
Why?
|
| Staurosporine | 4 | 2004 | 240 | 0.170 |
Why?
|
| Mutation, Missense | 4 | 2019 | 2589 | 0.170 |
Why?
|
| Phenotype | 18 | 2024 | 16721 | 0.160 |
Why?
|
| Restless Legs Syndrome | 1 | 2022 | 235 | 0.160 |
Why?
|
| Azacitidine | 5 | 2024 | 334 | 0.160 |
Why?
|
| Thromboplastin | 2 | 2012 | 289 | 0.160 |
Why?
|
| Flow Cytometry | 15 | 2015 | 5881 | 0.160 |
Why?
|
| Neoplastic Cells, Circulating | 4 | 2014 | 950 | 0.160 |
Why?
|
| Quantitative Trait, Heritable | 2 | 2001 | 541 | 0.160 |
Why?
|
| Antibody Affinity | 1 | 2020 | 251 | 0.160 |
Why?
|
| SEER Program | 5 | 2017 | 1446 | 0.160 |
Why?
|
| Thrombocythemia, Essential | 1 | 2020 | 114 | 0.160 |
Why?
|
| Lymphoma, Mantle-Cell | 3 | 2012 | 238 | 0.160 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 5 | 2015 | 69 | 0.160 |
Why?
|
| Gene Expression | 10 | 2022 | 7584 | 0.160 |
Why?
|
| beta 2-Microglobulin | 2 | 2018 | 330 | 0.160 |
Why?
|
| Receptors, Notch | 2 | 2021 | 752 | 0.160 |
Why?
|
| Substrate Specificity | 2 | 2021 | 1752 | 0.160 |
Why?
|
| Administration, Oral | 11 | 2022 | 4015 | 0.160 |
Why?
|
| Chemokine CCL4 | 2 | 2016 | 124 | 0.160 |
Why?
|
| Radioactive Pollutants | 1 | 2018 | 13 | 0.160 |
Why?
|
| Repressor Proteins | 5 | 2018 | 2968 | 0.160 |
Why?
|
| Lysine | 2 | 2014 | 991 | 0.160 |
Why?
|
| Chernobyl Nuclear Accident | 1 | 2018 | 15 | 0.160 |
Why?
|
| Melanoma-Specific Antigens | 3 | 2018 | 75 | 0.160 |
Why?
|
| Drug Discovery | 2 | 2017 | 1064 | 0.160 |
Why?
|
| Incidence | 20 | 2024 | 21480 | 0.150 |
Why?
|
| Breast Neoplasms | 19 | 2023 | 21056 | 0.150 |
Why?
|
| Karyotyping | 9 | 2019 | 1178 | 0.150 |
Why?
|
| Cytophotometry | 1 | 2018 | 8 | 0.150 |
Why?
|
| Leukocytes, Mononuclear | 5 | 2021 | 1857 | 0.150 |
Why?
|
| Mycoses | 1 | 2022 | 389 | 0.150 |
Why?
|
| Transcription Factors | 12 | 2021 | 12131 | 0.150 |
Why?
|
| Toll-Like Receptors | 2 | 2013 | 583 | 0.150 |
Why?
|
| Genetic Heterogeneity | 3 | 2018 | 735 | 0.150 |
Why?
|
| Transcription Factor AP-1 | 2 | 2012 | 322 | 0.150 |
Why?
|
| Cohort Studies | 29 | 2024 | 41647 | 0.150 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2018 | 89 | 0.150 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2020 | 183 | 0.150 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 4 | 2018 | 308 | 0.150 |
Why?
|
| Ifosfamide | 4 | 2014 | 233 | 0.150 |
Why?
|
| Trans-Activators | 5 | 2013 | 2850 | 0.150 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2022 | 374 | 0.150 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2024 | 3737 | 0.150 |
Why?
|
| Genome, Human | 5 | 2021 | 4448 | 0.150 |
Why?
|
| Epoxy Compounds | 1 | 2018 | 136 | 0.150 |
Why?
|
| Hematology | 1 | 2021 | 243 | 0.150 |
Why?
|
| Animals, Genetically Modified | 9 | 2017 | 1560 | 0.150 |
Why?
|
| Case-Control Studies | 23 | 2018 | 22222 | 0.150 |
Why?
|
| RNA, Neoplasm | 1 | 2020 | 745 | 0.150 |
Why?
|
| Tumor Escape | 1 | 2021 | 371 | 0.150 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2022 | 328 | 0.150 |
Why?
|
| Alcoholism | 2 | 1999 | 1975 | 0.150 |
Why?
|
| Maximum Tolerated Dose | 6 | 2019 | 898 | 0.150 |
Why?
|
| Event-Related Potentials, P300 | 1 | 1999 | 150 | 0.140 |
Why?
|
| Proportional Hazards Models | 16 | 2017 | 12509 | 0.140 |
Why?
|
| Fusobacterium | 1 | 2017 | 56 | 0.140 |
Why?
|
| Death, Sudden | 1 | 2019 | 300 | 0.140 |
Why?
|
| Immunity, Innate | 6 | 2013 | 3081 | 0.140 |
Why?
|
| Glutathione Transferase | 3 | 2004 | 562 | 0.140 |
Why?
|
| Homeodomain Proteins | 6 | 2013 | 2428 | 0.140 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 2016 | 1365 | 0.140 |
Why?
|
| Immunophenotyping | 12 | 2016 | 1866 | 0.140 |
Why?
|
| Thalidomide | 5 | 2016 | 886 | 0.140 |
Why?
|
| rac GTP-Binding Proteins | 1 | 2018 | 164 | 0.140 |
Why?
|
| Macrolides | 1 | 2018 | 204 | 0.140 |
Why?
|
| K562 Cells | 7 | 2019 | 649 | 0.140 |
Why?
|
| Infusions, Intravenous | 12 | 2015 | 2229 | 0.140 |
Why?
|
| Cyclin-Dependent Kinase 6 | 2 | 2018 | 352 | 0.140 |
Why?
|
| Aspartate-Ammonia Ligase | 2 | 2014 | 18 | 0.140 |
Why?
|
| Stroke | 1 | 2019 | 9747 | 0.140 |
Why?
|
| Tumor Suppressor Proteins | 8 | 2020 | 2796 | 0.140 |
Why?
|
| CpG Islands | 5 | 2024 | 1207 | 0.140 |
Why?
|
| Premedication | 1 | 2018 | 244 | 0.140 |
Why?
|
| Linear Models | 1 | 2007 | 5876 | 0.140 |
Why?
|
| Histone Code | 1 | 2018 | 159 | 0.140 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2013 | 1061 | 0.140 |
Why?
|
| High-Throughput Screening Assays | 3 | 2020 | 938 | 0.140 |
Why?
|
| Genetic Markers | 6 | 2012 | 2601 | 0.140 |
Why?
|
| Immunoglobulin Class Switching | 2 | 2015 | 289 | 0.140 |
Why?
|
| Thymidylate Synthase | 1 | 2016 | 73 | 0.140 |
Why?
|
| Thromboembolism | 2 | 2014 | 1003 | 0.140 |
Why?
|
| Live Birth | 1 | 2020 | 518 | 0.140 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2018 | 246 | 0.140 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 4 | 2021 | 1106 | 0.130 |
Why?
|
| Guanine Nucleotide Exchange Factors | 2 | 2018 | 569 | 0.130 |
Why?
|
| Gene Frequency | 8 | 2020 | 3624 | 0.130 |
Why?
|
| Glioblastoma | 3 | 2023 | 3459 | 0.130 |
Why?
|
| CD40 Ligand | 2 | 2012 | 528 | 0.130 |
Why?
|
| Atovaquone | 1 | 2016 | 56 | 0.130 |
Why?
|
| Multivariate Analysis | 13 | 2018 | 12057 | 0.130 |
Why?
|
| Brain Stem Neoplasms | 1 | 2018 | 192 | 0.130 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2021 | 752 | 0.130 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 | 2016 | 10 | 0.130 |
Why?
|
| Histocompatibility Testing | 5 | 2023 | 726 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-myb | 2 | 2007 | 82 | 0.130 |
Why?
|
| Mitoxantrone | 4 | 2019 | 148 | 0.130 |
Why?
|
| STAT1 Transcription Factor | 4 | 2013 | 339 | 0.130 |
Why?
|
| Carcinoma, Endometrioid | 2 | 2014 | 272 | 0.130 |
Why?
|
| DNA Damage | 6 | 2021 | 2457 | 0.130 |
Why?
|
| Spliceosomes | 2 | 2018 | 116 | 0.130 |
Why?
|
| Pituitary Neoplasms | 2 | 2018 | 1321 | 0.130 |
Why?
|
| Hydroxamic Acids | 2 | 2018 | 483 | 0.130 |
Why?
|
| Metronidazole | 1 | 2017 | 236 | 0.130 |
Why?
|
| Adenine | 6 | 2022 | 994 | 0.130 |
Why?
|
| Ribosomal Proteins | 3 | 2015 | 366 | 0.130 |
Why?
|
| RNA, Small Interfering | 5 | 2018 | 3421 | 0.130 |
Why?
|
| RNA-Binding Protein FUS | 1 | 2016 | 76 | 0.130 |
Why?
|
| Microcirculation | 2 | 2019 | 1280 | 0.130 |
Why?
|
| Epitopes | 2 | 2021 | 2523 | 0.130 |
Why?
|
| Gene Dosage | 4 | 2018 | 1216 | 0.130 |
Why?
|
| Genetic Variation | 7 | 2021 | 6610 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 8 | 2016 | 4044 | 0.130 |
Why?
|
| Hydrocarbons | 1 | 2016 | 105 | 0.130 |
Why?
|
| Cell Survival | 10 | 2018 | 5746 | 0.130 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2015 | 1165 | 0.130 |
Why?
|
| Point Mutation | 4 | 2011 | 1590 | 0.130 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2018 | 644 | 0.130 |
Why?
|
| Estrogen Receptor alpha | 1 | 2020 | 578 | 0.130 |
Why?
|
| Mice, Knockout | 11 | 2021 | 14447 | 0.130 |
Why?
|
| Killer Cells, Natural | 3 | 2020 | 2210 | 0.120 |
Why?
|
| Oncogenes | 2 | 2018 | 1235 | 0.120 |
Why?
|
| Oncogene Proteins | 3 | 2012 | 710 | 0.120 |
Why?
|
| Symbiosis | 1 | 2018 | 297 | 0.120 |
Why?
|
| Abortion, Spontaneous | 1 | 2020 | 536 | 0.120 |
Why?
|
| Quinazolines | 3 | 2017 | 1364 | 0.120 |
Why?
|
| Neoadjuvant Therapy | 3 | 2022 | 2895 | 0.120 |
Why?
|
| Gout | 1 | 2022 | 620 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 13 | 2024 | 22331 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2016 | 386 | 0.120 |
Why?
|
| Idarubicin | 4 | 2019 | 59 | 0.120 |
Why?
|
| Tissue Banks | 1 | 2016 | 183 | 0.120 |
Why?
|
| Genome | 3 | 2011 | 1753 | 0.120 |
Why?
|
| Glycogen Synthase | 1 | 2015 | 62 | 0.120 |
Why?
|
| Receptors, Calcitriol | 2 | 2008 | 361 | 0.120 |
Why?
|
| NF-kappa B | 7 | 2021 | 2485 | 0.120 |
Why?
|
| Gene Regulatory Networks | 2 | 2021 | 1749 | 0.120 |
Why?
|
| PPAR gamma | 1 | 2018 | 483 | 0.120 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2015 | 105 | 0.120 |
Why?
|
| Gene Fusion | 1 | 2018 | 357 | 0.120 |
Why?
|
| Platelet Count | 4 | 2020 | 782 | 0.120 |
Why?
|
| Sarcoma, Alveolar Soft Part | 1 | 2015 | 44 | 0.120 |
Why?
|
| Immunoconjugates | 2 | 2019 | 981 | 0.120 |
Why?
|
| Glucocorticoids | 3 | 2020 | 2132 | 0.120 |
Why?
|
| Warfarin | 3 | 2022 | 1494 | 0.120 |
Why?
|
| Recombinant Proteins | 11 | 2012 | 6493 | 0.120 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 2 | 2020 | 58 | 0.120 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 3 | 2006 | 266 | 0.120 |
Why?
|
| Antigens, CD19 | 4 | 2024 | 443 | 0.120 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 2014 | 17 | 0.120 |
Why?
|
| Citric Acid Cycle | 1 | 2016 | 228 | 0.120 |
Why?
|
| Neoplasms, Experimental | 2 | 2019 | 1229 | 0.120 |
Why?
|
| Megakaryocytes | 2 | 2018 | 557 | 0.120 |
Why?
|
| Comparative Genomic Hybridization | 3 | 2010 | 476 | 0.120 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2015 | 75 | 0.120 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2020 | 2056 | 0.120 |
Why?
|
| Age Factors | 17 | 2018 | 18380 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 10 | 2018 | 5786 | 0.120 |
Why?
|
| Anilides | 1 | 2017 | 415 | 0.110 |
Why?
|
| Glioma | 3 | 2018 | 3493 | 0.110 |
Why?
|
| Telomere | 1 | 2020 | 943 | 0.110 |
Why?
|
| Retinoblastoma Protein | 1 | 2018 | 666 | 0.110 |
Why?
|
| Mitochondria, Heart | 1 | 2016 | 227 | 0.110 |
Why?
|
| Blood Coagulation Factors | 1 | 2017 | 371 | 0.110 |
Why?
|
| STAT3 Transcription Factor | 2 | 2016 | 870 | 0.110 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2016 | 2047 | 0.110 |
Why?
|
| Glycogen | 1 | 2015 | 251 | 0.110 |
Why?
|
| Core Binding Factors | 1 | 2014 | 29 | 0.110 |
Why?
|
| HMGN1 Protein | 1 | 2014 | 27 | 0.110 |
Why?
|
| DNA Breaks, Double-Stranded | 2 | 2016 | 604 | 0.110 |
Why?
|
| Cell Differentiation | 15 | 2017 | 11640 | 0.110 |
Why?
|
| Sarcoma, Myeloid | 1 | 2014 | 52 | 0.110 |
Why?
|
| MAP Kinase Signaling System | 3 | 2016 | 1490 | 0.110 |
Why?
|
| Thrombin | 1 | 2017 | 602 | 0.110 |
Why?
|
| Tretinoin | 2 | 2013 | 524 | 0.110 |
Why?
|
| Interleukin-11 | 2 | 2006 | 58 | 0.110 |
Why?
|
| T-Lymphocytes, Cytotoxic | 5 | 2025 | 1801 | 0.110 |
Why?
|
| Acyltransferases | 1 | 2016 | 305 | 0.110 |
Why?
|
| Enhancer Elements, Genetic | 3 | 2018 | 1365 | 0.110 |
Why?
|
| Mice, Transgenic | 9 | 2019 | 9550 | 0.110 |
Why?
|
| Neoplastic Stem Cells | 3 | 2014 | 1352 | 0.110 |
Why?
|
| Disease Models, Animal | 10 | 2021 | 18294 | 0.110 |
Why?
|
| Neoplasm Transplantation | 5 | 2018 | 2014 | 0.110 |
Why?
|
| Loss of Heterozygosity | 5 | 2020 | 663 | 0.110 |
Why?
|
| Cell Line | 12 | 2024 | 15543 | 0.110 |
Why?
|
| Cell Cycle | 6 | 2012 | 2920 | 0.110 |
Why?
|
| Interleukin-3 | 4 | 2011 | 423 | 0.110 |
Why?
|
| DNA | 4 | 2024 | 7202 | 0.110 |
Why?
|
| Amifostine | 2 | 2004 | 39 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-bcr | 1 | 2013 | 21 | 0.110 |
Why?
|
| Transplantation Chimera | 4 | 2014 | 609 | 0.110 |
Why?
|
| Interleukin-1alpha | 1 | 2014 | 88 | 0.110 |
Why?
|
| Siblings | 4 | 2015 | 828 | 0.110 |
Why?
|
| Phosphorylation | 9 | 2024 | 8278 | 0.110 |
Why?
|
| Vulvar Neoplasms | 1 | 2016 | 270 | 0.110 |
Why?
|
| Lymphoid Enhancer-Binding Factor 1 | 2 | 2012 | 84 | 0.110 |
Why?
|
| TYK2 Kinase | 1 | 2013 | 38 | 0.100 |
Why?
|
| Radiation-Protective Agents | 2 | 2004 | 87 | 0.100 |
Why?
|
| Histones | 2 | 2014 | 2584 | 0.100 |
Why?
|
| Interferon-gamma | 8 | 2023 | 3160 | 0.100 |
Why?
|
| Arabinonucleosides | 1 | 2013 | 35 | 0.100 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2014 | 916 | 0.100 |
Why?
|
| DNA Primers | 6 | 2014 | 2825 | 0.100 |
Why?
|
| Nanowires | 1 | 2012 | 31 | 0.100 |
Why?
|
| Mice, SCID | 5 | 2021 | 2630 | 0.100 |
Why?
|
| Adenine Nucleotides | 1 | 2013 | 110 | 0.100 |
Why?
|
| Aspirin | 2 | 2023 | 3134 | 0.100 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2014 | 125 | 0.100 |
Why?
|
| Farnesyltranstransferase | 1 | 2012 | 70 | 0.100 |
Why?
|
| Bone Marrow Purging | 6 | 2007 | 108 | 0.100 |
Why?
|
| Neovascularization, Pathologic | 4 | 2013 | 2631 | 0.100 |
Why?
|
| Fatigue | 4 | 2023 | 1549 | 0.100 |
Why?
|
| T-Lymphocytes, Regulatory | 5 | 2018 | 3111 | 0.100 |
Why?
|
| Cytogenetics | 2 | 2010 | 198 | 0.100 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2015 | 707 | 0.100 |
Why?
|
| Down Syndrome | 3 | 2018 | 915 | 0.100 |
Why?
|
| Gallium | 2 | 2004 | 30 | 0.100 |
Why?
|
| Jurkat Cells | 4 | 2019 | 737 | 0.100 |
Why?
|
| Silicon | 1 | 2012 | 141 | 0.100 |
Why?
|
| Blood | 1 | 2014 | 597 | 0.100 |
Why?
|
| Cell Movement | 8 | 2018 | 5194 | 0.100 |
Why?
|
| Molecular Targeted Therapy | 3 | 2018 | 2822 | 0.100 |
Why?
|
| Blood Platelets | 3 | 2019 | 2464 | 0.100 |
Why?
|
| Carmustine | 1 | 2012 | 137 | 0.100 |
Why?
|
| Indoles | 4 | 2018 | 1839 | 0.100 |
Why?
|
| Ferritins | 1 | 2015 | 600 | 0.100 |
Why?
|
| Molecular Sequence Data | 13 | 2014 | 17594 | 0.100 |
Why?
|
| Coagulants | 1 | 2012 | 44 | 0.100 |
Why?
|
| Hemochromatosis | 1 | 2013 | 175 | 0.100 |
Why?
|
| Cells, Cultured | 11 | 2018 | 18973 | 0.100 |
Why?
|
| Endonucleases | 2 | 2005 | 372 | 0.100 |
Why?
|
| Activating Transcription Factors | 1 | 2011 | 30 | 0.100 |
Why?
|
| Oxidative Phosphorylation | 3 | 2024 | 502 | 0.100 |
Why?
|
| Membrane Glycoproteins | 4 | 2008 | 3690 | 0.100 |
Why?
|
| Peptide Chain Initiation, Translational | 1 | 2012 | 100 | 0.090 |
Why?
|
| Clinical Trials, Phase III as Topic | 4 | 2020 | 878 | 0.090 |
Why?
|
| Ventricular Function, Left | 5 | 2023 | 3928 | 0.090 |
Why?
|
| Genes, Immunoglobulin | 4 | 2011 | 285 | 0.090 |
Why?
|
| Risk Assessment | 11 | 2020 | 24283 | 0.090 |
Why?
|
| Hypertension, Pulmonary | 1 | 2022 | 1604 | 0.090 |
Why?
|
| Genes, ras | 3 | 2007 | 658 | 0.090 |
Why?
|
| Mutagenesis, Insertional | 2 | 2018 | 661 | 0.090 |
Why?
|
| Computational Biology | 2 | 2021 | 3559 | 0.090 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2015 | 595 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 3 | 2021 | 7478 | 0.090 |
Why?
|
| Glutathione S-Transferase pi | 3 | 2006 | 99 | 0.090 |
Why?
|
| Quality of Life | 7 | 2023 | 13461 | 0.090 |
Why?
|
| Bone and Bones | 2 | 2012 | 2554 | 0.090 |
Why?
|
| Endometrium | 1 | 2014 | 406 | 0.090 |
Why?
|
| Sex Factors | 4 | 2020 | 10602 | 0.090 |
Why?
|
| Factor VIIa | 1 | 2012 | 102 | 0.090 |
Why?
|
| Fluorescent Antibody Technique | 3 | 2021 | 2476 | 0.090 |
Why?
|
| Epitopes, T-Lymphocyte | 3 | 2014 | 825 | 0.090 |
Why?
|
| Chromosome Breakage | 1 | 2011 | 159 | 0.090 |
Why?
|
| Toll-Like Receptor 9 | 2 | 2009 | 197 | 0.090 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2022 | 1758 | 0.090 |
Why?
|
| Kidney Neoplasms | 3 | 2020 | 4274 | 0.090 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2015 | 272 | 0.090 |
Why?
|
| Erythroid Cells | 2 | 2013 | 237 | 0.090 |
Why?
|
| Cardiomyopathies | 3 | 2012 | 2067 | 0.090 |
Why?
|
| Monitoring, Immunologic | 2 | 2021 | 99 | 0.090 |
Why?
|
| YY1 Transcription Factor | 1 | 2011 | 60 | 0.090 |
Why?
|
| Genes, T-Cell Receptor gamma | 1 | 2010 | 15 | 0.090 |
Why?
|
| Protein Kinase C | 2 | 2007 | 1202 | 0.090 |
Why?
|
| Bacteremia | 1 | 2018 | 989 | 0.090 |
Why?
|
| Immunotherapy, Active | 1 | 2010 | 58 | 0.090 |
Why?
|
| Chromosome Mapping | 3 | 2013 | 4618 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 11 | 2019 | 18071 | 0.090 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2011 | 101 | 0.090 |
Why?
|
| Multiprotein Complexes | 1 | 2017 | 1107 | 0.090 |
Why?
|
| Withholding Treatment | 1 | 2015 | 621 | 0.090 |
Why?
|
| Neutrophils | 2 | 2023 | 3776 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 3 | 3 | 2012 | 323 | 0.090 |
Why?
|
| Thyroid Neoplasms | 3 | 2018 | 2371 | 0.090 |
Why?
|
| Blotting, Western | 7 | 2013 | 5020 | 0.090 |
Why?
|
| Gene Rearrangement | 5 | 2018 | 1144 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 21 | 3 | 2014 | 228 | 0.090 |
Why?
|
| STAT Transcription Factors | 2 | 2023 | 189 | 0.090 |
Why?
|
| Myocardial Stunning | 1 | 2010 | 67 | 0.090 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2010 | 81 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 2 | 2016 | 360 | 0.090 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2020 | 3181 | 0.090 |
Why?
|
| Vitamin D | 4 | 2008 | 3272 | 0.090 |
Why?
|
| HIV Antibodies | 1 | 2017 | 1337 | 0.090 |
Why?
|
| Philadelphia Chromosome | 4 | 2022 | 119 | 0.090 |
Why?
|
| Neoplasm Metastasis | 13 | 2017 | 4893 | 0.090 |
Why?
|
| beta-Galactosidase | 2 | 2008 | 572 | 0.090 |
Why?
|
| Forkhead Transcription Factors | 2 | 2014 | 1624 | 0.090 |
Why?
|
| PAX2 Transcription Factor | 1 | 2010 | 86 | 0.090 |
Why?
|
| Erwinia | 1 | 2010 | 22 | 0.090 |
Why?
|
| Linkage Disequilibrium | 4 | 2011 | 1997 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 13 | 3 | 2010 | 191 | 0.090 |
Why?
|
| Leukocyte Count | 4 | 2023 | 1602 | 0.090 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2015 | 777 | 0.090 |
Why?
|
| Predictive Value of Tests | 16 | 2020 | 15398 | 0.080 |
Why?
|
| Daunorubicin | 2 | 2024 | 157 | 0.080 |
Why?
|
| Boronic Acids | 4 | 2013 | 916 | 0.080 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2013 | 2056 | 0.080 |
Why?
|
| Feasibility Studies | 8 | 2019 | 5302 | 0.080 |
Why?
|
| Fractures, Bone | 3 | 2017 | 2041 | 0.080 |
Why?
|
| Lymphocytes | 3 | 2012 | 2599 | 0.080 |
Why?
|
| Janus Kinases | 2 | 2023 | 253 | 0.080 |
Why?
|
| DNA Repair | 3 | 2021 | 2048 | 0.080 |
Why?
|
| Ovarian Neoplasms | 2 | 2022 | 4900 | 0.080 |
Why?
|
| Interleukin-2 | 4 | 2011 | 1896 | 0.080 |
Why?
|
| Hyperplasia | 2 | 2017 | 1144 | 0.080 |
Why?
|
| Diabetes Mellitus, Experimental | 2 | 2007 | 1118 | 0.080 |
Why?
|
| Sirolimus | 3 | 2012 | 1545 | 0.080 |
Why?
|
| Troponin T | 2 | 2012 | 785 | 0.080 |
Why?
|
| Interferon-alpha | 4 | 2022 | 910 | 0.080 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2010 | 121 | 0.080 |
Why?
|
| GTP Phosphohydrolases | 1 | 2013 | 523 | 0.080 |
Why?
|
| Teratoma | 1 | 2012 | 401 | 0.080 |
Why?
|
| Oxidoreductases Acting on CH-CH Group Donors | 1 | 2011 | 173 | 0.080 |
Why?
|
| Inheritance Patterns | 1 | 2012 | 345 | 0.080 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2010 | 202 | 0.080 |
Why?
|
| Integrins | 1 | 2014 | 840 | 0.080 |
Why?
|
| Codon, Terminator | 1 | 2010 | 125 | 0.080 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2011 | 241 | 0.080 |
Why?
|
| Fibroblasts | 2 | 2018 | 4159 | 0.080 |
Why?
|
| Antigens, Surface | 3 | 2010 | 1617 | 0.080 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 1 | 2009 | 133 | 0.080 |
Why?
|
| Cisplatin | 7 | 2014 | 1658 | 0.080 |
Why?
|
| Haplotypes | 5 | 2019 | 2728 | 0.080 |
Why?
|
| Antigen-Antibody Complex | 1 | 2011 | 508 | 0.080 |
Why?
|
| Gene Library | 5 | 2011 | 1067 | 0.080 |
Why?
|
| Uniparental Disomy | 1 | 2009 | 46 | 0.080 |
Why?
|
| Acute Disease | 10 | 2019 | 7232 | 0.080 |
Why?
|
| mRNA Cleavage and Polyadenylation Factors | 2 | 2014 | 102 | 0.080 |
Why?
|
| Tobacco Smoke Pollution | 2 | 2006 | 827 | 0.080 |
Why?
|
| beta Catenin | 1 | 2014 | 1043 | 0.080 |
Why?
|
| Microfilament Proteins | 1 | 2014 | 1130 | 0.080 |
Why?
|
| Receptors, IgE | 1 | 2010 | 374 | 0.080 |
Why?
|
| Hematologic Diseases | 5 | 2006 | 500 | 0.080 |
Why?
|
| Macrophages | 3 | 2020 | 5772 | 0.080 |
Why?
|
| Germ-Free Life | 2 | 2020 | 187 | 0.080 |
Why?
|
| Hemorrhage | 5 | 2023 | 3461 | 0.080 |
Why?
|
| Escherichia coli Proteins | 1 | 2015 | 1057 | 0.080 |
Why?
|
| Neural Crest | 1 | 2011 | 278 | 0.080 |
Why?
|
| Oxidative Stress | 4 | 2015 | 3141 | 0.080 |
Why?
|
| Genome-Wide Association Study | 5 | 2019 | 12807 | 0.080 |
Why?
|
| Isoenzymes | 2 | 2003 | 1689 | 0.080 |
Why?
|
| Echocardiography | 4 | 2018 | 5045 | 0.080 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 7836 | 0.080 |
Why?
|
| Interleukin-12 | 2 | 2003 | 579 | 0.080 |
Why?
|
| Leukemia, Experimental | 3 | 2016 | 225 | 0.080 |
Why?
|
| Blast Crisis | 2 | 2006 | 102 | 0.080 |
Why?
|
| Tissue Donors | 5 | 2024 | 2395 | 0.080 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2013 | 1534 | 0.080 |
Why?
|
| Drug Therapy, Combination | 9 | 2011 | 6309 | 0.080 |
Why?
|
| Carcinoma | 3 | 2008 | 2312 | 0.080 |
Why?
|
| Pyrazines | 4 | 2013 | 1204 | 0.070 |
Why?
|
| Reproducibility of Results | 11 | 2019 | 20125 | 0.070 |
Why?
|
| Immunoglobulin A | 1 | 2012 | 995 | 0.070 |
Why?
|
| Granzymes | 1 | 2010 | 278 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-rel | 2 | 2005 | 71 | 0.070 |
Why?
|
| Carcinoma, Medullary | 2 | 1999 | 114 | 0.070 |
Why?
|
| ras Proteins | 3 | 2024 | 1053 | 0.070 |
Why?
|
| Behavior | 1 | 2011 | 535 | 0.070 |
Why?
|
| Benzoquinones | 1 | 2008 | 198 | 0.070 |
Why?
|
| Vaccines, Subunit | 1 | 2008 | 158 | 0.070 |
Why?
|
| Postoperative Hemorrhage | 1 | 2012 | 413 | 0.070 |
Why?
|
| Insurance Coverage | 2 | 2017 | 1944 | 0.070 |
Why?
|
| Heart-Assist Devices | 1 | 2019 | 1296 | 0.070 |
Why?
|
| Cranial Irradiation | 2 | 2007 | 385 | 0.070 |
Why?
|
| Escherichia coli | 3 | 2015 | 4214 | 0.070 |
Why?
|
| Craniopharyngioma | 1 | 2010 | 276 | 0.070 |
Why?
|
| Gases | 1 | 2008 | 206 | 0.070 |
Why?
|
| Down-Regulation | 5 | 2017 | 2927 | 0.070 |
Why?
|
| Bleomycin | 4 | 2016 | 491 | 0.070 |
Why?
|
| Ultrasonography | 2 | 2019 | 5993 | 0.070 |
Why?
|
| Gallium Radioisotopes | 2 | 2000 | 195 | 0.070 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2012 | 245 | 0.070 |
Why?
|
| Intrauterine Devices | 1 | 2009 | 115 | 0.070 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 2418 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 6 | 2015 | 3807 | 0.070 |
Why?
|
| Risk | 8 | 2017 | 9591 | 0.070 |
Why?
|
| MicroRNAs | 3 | 2014 | 3785 | 0.070 |
Why?
|
| Biopsy | 5 | 2018 | 6763 | 0.070 |
Why?
|
| Mutagenesis | 1 | 2011 | 1228 | 0.070 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2019 | 1880 | 0.070 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 2 | 2014 | 368 | 0.070 |
Why?
|
| Transgenes | 3 | 2018 | 1015 | 0.070 |
Why?
|
| Alu Elements | 1 | 2007 | 115 | 0.070 |
Why?
|
| Antibodies, Neutralizing | 1 | 2017 | 2010 | 0.070 |
Why?
|
| Insurance, Health | 2 | 2017 | 2520 | 0.070 |
Why?
|
| Immunoglobulin M | 1 | 2012 | 1528 | 0.070 |
Why?
|
| United States | 14 | 2022 | 72898 | 0.070 |
Why?
|
| Bacteria | 1 | 2018 | 2209 | 0.070 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 3247 | 0.070 |
Why?
|
| Lactams, Macrocyclic | 1 | 2008 | 318 | 0.070 |
Why?
|
| Hospital Mortality | 1 | 2021 | 5343 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-kit | 3 | 2009 | 723 | 0.070 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2010 | 1132 | 0.070 |
Why?
|
| Actins | 1 | 2014 | 2056 | 0.070 |
Why?
|
| Odds Ratio | 7 | 2022 | 9649 | 0.070 |
Why?
|
| Contraceptives, Oral | 1 | 2009 | 559 | 0.070 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2006 | 45 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 2 | 2022 | 5444 | 0.070 |
Why?
|
| Wilms Tumor | 2 | 2000 | 379 | 0.070 |
Why?
|
| Pneumonia | 2 | 2012 | 2157 | 0.070 |
Why?
|
| Cell Separation | 4 | 2009 | 1718 | 0.070 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2008 | 169 | 0.070 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2007 | 97 | 0.070 |
Why?
|
| Oxidants, Photochemical | 2 | 2004 | 77 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 14 | 5 | 2010 | 285 | 0.070 |
Why?
|
| Heat-Shock Response | 1 | 2007 | 179 | 0.060 |
Why?
|
| Coronavirus Infections | 1 | 2024 | 3100 | 0.060 |
Why?
|
| HEK293 Cells | 4 | 2018 | 4258 | 0.060 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 2 | 2007 | 113 | 0.060 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 3 | 2010 | 1140 | 0.060 |
Why?
|
| DNA Modification Methylases | 2 | 2018 | 207 | 0.060 |
Why?
|
| RNA, Messenger | 10 | 2015 | 12769 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinase | 2 | 2019 | 124 | 0.060 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2008 | 248 | 0.060 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2008 | 422 | 0.060 |
Why?
|
| Genes, T-Cell Receptor beta | 2 | 2010 | 70 | 0.060 |
Why?
|
| Polymorphism, Restriction Fragment Length | 3 | 2004 | 766 | 0.060 |
Why?
|
| beta-Thalassemia | 1 | 2008 | 233 | 0.060 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 2006 | 175 | 0.060 |
Why?
|
| Benzamides | 6 | 2012 | 1377 | 0.060 |
Why?
|
| Biomimetics | 1 | 2007 | 168 | 0.060 |
Why?
|
| Mice, Mutant Strains | 3 | 2019 | 1745 | 0.060 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2016 | 1484 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2008 | 591 | 0.060 |
Why?
|
| Immunization, Passive | 1 | 2008 | 616 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 1 | 2005 | 29 | 0.060 |
Why?
|
| Positron-Emission Tomography | 3 | 2010 | 6547 | 0.060 |
Why?
|
| Metabolomics | 1 | 2015 | 1668 | 0.060 |
Why?
|
| Adaptive Immunity | 1 | 2010 | 734 | 0.060 |
Why?
|
| Enzyme Activation | 4 | 2018 | 3586 | 0.060 |
Why?
|
| Immunoglobulin G | 3 | 2024 | 4528 | 0.060 |
Why?
|
| Telemedicine | 1 | 2023 | 3105 | 0.060 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2007 | 234 | 0.060 |
Why?
|
| Carotid Artery Diseases | 1 | 2011 | 874 | 0.060 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 2005 | 67 | 0.060 |
Why?
|
| Heart Ventricles | 2 | 2019 | 3832 | 0.060 |
Why?
|
| Brassica | 1 | 2004 | 40 | 0.060 |
Why?
|
| Transaminases | 1 | 2006 | 199 | 0.060 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2007 | 393 | 0.060 |
Why?
|
| Atrial Fibrillation | 1 | 2023 | 5189 | 0.060 |
Why?
|
| Brain Diseases | 1 | 2014 | 1546 | 0.060 |
Why?
|
| Isoquinolines | 2 | 2016 | 350 | 0.060 |
Why?
|
| Blood Vessels | 1 | 2010 | 1113 | 0.060 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2004 | 50 | 0.060 |
Why?
|
| Herpesvirus 3, Human | 1 | 2006 | 159 | 0.060 |
Why?
|
| Cloning, Molecular | 4 | 2018 | 4165 | 0.060 |
Why?
|
| Protein Array Analysis | 3 | 2012 | 399 | 0.060 |
Why?
|
| Lymphoma, T-Cell | 1 | 2007 | 309 | 0.060 |
Why?
|
| Morbidity | 2 | 2021 | 1749 | 0.060 |
Why?
|
| ADP-Ribosylation Factors | 1 | 2005 | 130 | 0.060 |
Why?
|
| Cell Shape | 2 | 2016 | 373 | 0.060 |
Why?
|
| Vascular Diseases | 1 | 2013 | 1159 | 0.060 |
Why?
|
| Embryonic Development | 1 | 2009 | 718 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2022 | 3537 | 0.060 |
Why?
|
| RNA Interference | 4 | 2014 | 2832 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 4 | 2004 | 2921 | 0.060 |
Why?
|
| Proto-Oncogenes | 2 | 2003 | 320 | 0.060 |
Why?
|
| Immunoglobulin Joining Region | 1 | 2004 | 37 | 0.060 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2010 | 845 | 0.060 |
Why?
|
| Chemokine CCL2 | 2 | 2009 | 602 | 0.060 |
Why?
|
| Nervous System Diseases | 2 | 2013 | 1660 | 0.060 |
Why?
|
| Proteins | 5 | 2017 | 5995 | 0.060 |
Why?
|
| Tissue Preservation | 1 | 2004 | 169 | 0.060 |
Why?
|
| Metals | 1 | 2008 | 710 | 0.060 |
Why?
|
| Cytogenetic Analysis | 3 | 2011 | 269 | 0.060 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2024 | 36 | 0.060 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2005 | 246 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 12 | 2 | 2014 | 430 | 0.060 |
Why?
|
| Fluorouracil | 7 | 1999 | 1648 | 0.060 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2004 | 107 | 0.060 |
Why?
|
| CDC2-CDC28 Kinases | 1 | 2004 | 111 | 0.060 |
Why?
|
| Matrix Metalloproteinases | 1 | 2006 | 392 | 0.060 |
Why?
|
| Postpartum Hemorrhage | 1 | 2008 | 276 | 0.060 |
Why?
|
| Protein Binding | 4 | 2018 | 9296 | 0.060 |
Why?
|
| Isoantibodies | 1 | 2008 | 681 | 0.060 |
Why?
|
| Dactinomycin | 1 | 2004 | 304 | 0.050 |
Why?
|
| Mammography | 2 | 2013 | 2423 | 0.050 |
Why?
|
| Freezing | 1 | 2004 | 310 | 0.050 |
Why?
|
| Semen Preservation | 1 | 2003 | 35 | 0.050 |
Why?
|
| Metaphase | 1 | 2003 | 144 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 4 | 2010 | 4348 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 1731 | 0.050 |
Why?
|
| Protein Isoforms | 4 | 2013 | 1718 | 0.050 |
Why?
|
| Thiazoles | 1 | 2011 | 1529 | 0.050 |
Why?
|
| Body Mass Index | 3 | 2023 | 13039 | 0.050 |
Why?
|
| Salvage Therapy | 5 | 2010 | 1272 | 0.050 |
Why?
|
| Chromatin Immunoprecipitation | 3 | 2013 | 857 | 0.050 |
Why?
|
| Interphase | 1 | 2003 | 226 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 1998 | 616 | 0.050 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2005 | 170 | 0.050 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2012 | 1736 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2020 | 1314 | 0.050 |
Why?
|
| Herpes Zoster | 1 | 2006 | 252 | 0.050 |
Why?
|
| Antibodies, Antinuclear | 1 | 2004 | 340 | 0.050 |
Why?
|
| Central Nervous System Diseases | 1 | 2007 | 518 | 0.050 |
Why?
|
| Mast Cells | 1 | 2010 | 1412 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2013 | 2880 | 0.050 |
Why?
|
| Retinal Vessels | 1 | 1989 | 863 | 0.050 |
Why?
|
| Platinum | 1 | 2004 | 218 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 2 | 2008 | 995 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2014 | 703 | 0.050 |
Why?
|
| Air Pollutants, Occupational | 2 | 2008 | 406 | 0.050 |
Why?
|
| Leukemia, T-Cell | 1 | 2003 | 102 | 0.050 |
Why?
|
| Granulocyte Precursor Cells | 2 | 2012 | 49 | 0.050 |
Why?
|
| Retinal Diseases | 1 | 1989 | 709 | 0.050 |
Why?
|
| Heart Failure | 3 | 2023 | 11840 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2017 | 5912 | 0.050 |
Why?
|
| Ozone | 2 | 2004 | 499 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 18 | 5 | 2006 | 247 | 0.050 |
Why?
|
| RNA Splicing | 2 | 2021 | 903 | 0.050 |
Why?
|
| Cryoprotective Agents | 1 | 2003 | 123 | 0.050 |
Why?
|
| Receptors, Chemokine | 2 | 2005 | 651 | 0.050 |
Why?
|
| Vaccines, DNA | 1 | 2024 | 279 | 0.050 |
Why?
|
| Liver Failure | 1 | 2004 | 252 | 0.050 |
Why?
|
| Cell Lineage | 4 | 2016 | 2573 | 0.050 |
Why?
|
| Esophageal Neoplasms | 3 | 1999 | 1661 | 0.050 |
Why?
|
| Interleukin-15 | 3 | 2011 | 186 | 0.050 |
Why?
|
| Asbestos | 1 | 2004 | 250 | 0.050 |
Why?
|
| Directly Observed Therapy | 1 | 2003 | 139 | 0.050 |
Why?
|
| Tamoxifen | 3 | 2018 | 963 | 0.050 |
Why?
|
| Sunlight | 1 | 2024 | 337 | 0.050 |
Why?
|
| Luciferases | 1 | 2004 | 713 | 0.050 |
Why?
|
| Epidemiologic Methods | 4 | 2011 | 1326 | 0.050 |
Why?
|
| Antibodies, Heterophile | 2 | 1999 | 128 | 0.050 |
Why?
|
| Sperm Motility | 1 | 2003 | 265 | 0.050 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2020 | 904 | 0.050 |
Why?
|
| Tissue Array Analysis | 2 | 2014 | 545 | 0.050 |
Why?
|
| Infant, Newborn | 10 | 2013 | 26349 | 0.050 |
Why?
|
| Tumor Burden | 3 | 2013 | 1885 | 0.050 |
Why?
|
| Exons | 3 | 2014 | 2391 | 0.050 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2022 | 151 | 0.050 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2003 | 281 | 0.050 |
Why?
|
| Lod Score | 2 | 2001 | 598 | 0.050 |
Why?
|
| Acetamides | 1 | 2003 | 260 | 0.050 |
Why?
|
| Spleen | 3 | 2018 | 2296 | 0.050 |
Why?
|
| Cell Count | 3 | 2014 | 1823 | 0.050 |
Why?
|
| Antibodies, Viral | 2 | 2024 | 3211 | 0.050 |
Why?
|
| Leukopoiesis | 1 | 2001 | 54 | 0.050 |
Why?
|
| Sensitivity and Specificity | 9 | 2017 | 14652 | 0.050 |
Why?
|
| Amino Acid Sequence | 5 | 2017 | 13400 | 0.050 |
Why?
|
| Superoxide Dismutase | 1 | 2004 | 593 | 0.050 |
Why?
|
| Homeostasis | 3 | 2020 | 3336 | 0.050 |
Why?
|
| Myocytes, Cardiac | 1 | 2010 | 1668 | 0.050 |
Why?
|
| Mechlorethamine | 2 | 2016 | 129 | 0.050 |
Why?
|
| Sulfites | 2 | 2014 | 83 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 8 | 2 | 2014 | 451 | 0.050 |
Why?
|
| Sialoglycoproteins | 1 | 2002 | 313 | 0.050 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2002 | 260 | 0.050 |
Why?
|
| Daptomycin | 1 | 2021 | 71 | 0.050 |
Why?
|
| World Health Organization | 2 | 2018 | 1328 | 0.050 |
Why?
|
| Cross-Sectional Studies | 8 | 2018 | 26313 | 0.050 |
Why?
|
| Integrases | 2 | 2018 | 520 | 0.050 |
Why?
|
| BCG Vaccine | 1 | 2004 | 380 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2015 | 3967 | 0.050 |
Why?
|
| Smoking | 5 | 2022 | 9081 | 0.050 |
Why?
|
| Drug Monitoring | 2 | 2008 | 962 | 0.050 |
Why?
|
| Drug Hypersensitivity | 1 | 2010 | 902 | 0.050 |
Why?
|
| Rhabdomyosarcoma | 1 | 2004 | 354 | 0.050 |
Why?
|
| Ataxia Telangiectasia | 2 | 1999 | 107 | 0.050 |
Why?
|
| Colorectal Neoplasms | 2 | 2017 | 6942 | 0.050 |
Why?
|
| Viral Matrix Proteins | 2 | 2012 | 192 | 0.050 |
Why?
|
| Double-Blind Method | 3 | 2024 | 12437 | 0.050 |
Why?
|
| Prednisolone | 1 | 2002 | 324 | 0.050 |
Why?
|
| Tomography, Emission-Computed | 1 | 2004 | 1006 | 0.040 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2012 | 1883 | 0.040 |
Why?
|
| Immunomodulation | 2 | 2018 | 547 | 0.040 |
Why?
|
| Telomere-Binding Proteins | 1 | 2021 | 122 | 0.040 |
Why?
|
| Phosphotyrosine | 2 | 2016 | 459 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2007 | 1505 | 0.040 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2000 | 49 | 0.040 |
Why?
|
| Analysis of Variance | 6 | 2008 | 6203 | 0.040 |
Why?
|
| Vacuolar Proton-Translocating ATPases | 1 | 2002 | 196 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 2 | 2023 | 1078 | 0.040 |
Why?
|
| Industrial Waste | 1 | 2000 | 24 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 2 | 2020 | 2035 | 0.040 |
Why?
|
| Chromatin | 2 | 2023 | 2980 | 0.040 |
Why?
|
| Cyclic AMP | 1 | 2004 | 1467 | 0.040 |
Why?
|
| Cancer Care Facilities | 2 | 2014 | 426 | 0.040 |
Why?
|
| Fuel Oils | 1 | 2000 | 36 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1989 | 2203 | 0.040 |
Why?
|
| Vanadium | 1 | 2000 | 54 | 0.040 |
Why?
|
| Quebec | 1 | 2020 | 140 | 0.040 |
Why?
|
| Beckwith-Wiedemann Syndrome | 1 | 2000 | 44 | 0.040 |
Why?
|
| Boron Compounds | 1 | 2022 | 196 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 3685 | 0.040 |
Why?
|
| Genetic Association Studies | 3 | 2014 | 2741 | 0.040 |
Why?
|
| Demography | 2 | 2023 | 1641 | 0.040 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2022 | 222 | 0.040 |
Why?
|
| Graft vs Tumor Effect | 1 | 2000 | 70 | 0.040 |
Why?
|
| Receptor-CD3 Complex, Antigen, T-Cell | 1 | 2000 | 67 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2011 | 412 | 0.040 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 2000 | 66 | 0.040 |
Why?
|
| Estradiol | 1 | 2007 | 1947 | 0.040 |
Why?
|
| HIV-1 | 1 | 2017 | 6944 | 0.040 |
Why?
|
| Embryo, Nonmammalian | 3 | 2009 | 907 | 0.040 |
Why?
|
| Insulin-Secreting Cells | 1 | 2007 | 898 | 0.040 |
Why?
|
| Citrates | 1 | 2000 | 130 | 0.040 |
Why?
|
| Lung Diseases | 2 | 2008 | 1940 | 0.040 |
Why?
|
| Mice, Nude | 5 | 2005 | 3618 | 0.040 |
Why?
|
| Ricin | 1 | 1999 | 72 | 0.040 |
Why?
|
| Medicare | 3 | 2022 | 6823 | 0.040 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2020 | 175 | 0.040 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 1999 | 975 | 0.040 |
Why?
|
| Spermatozoa | 1 | 2003 | 629 | 0.040 |
Why?
|
| Receptors, Interleukin-2 | 2 | 1998 | 561 | 0.040 |
Why?
|
| Drosophila Proteins | 2 | 1999 | 1697 | 0.040 |
Why?
|
| South America | 1 | 2019 | 179 | 0.040 |
Why?
|
| MART-1 Antigen | 2 | 2011 | 65 | 0.040 |
Why?
|
| Complementarity Determining Regions | 1 | 2000 | 154 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2012 | 5125 | 0.040 |
Why?
|
| Azithromycin | 1 | 2020 | 201 | 0.040 |
Why?
|
| Age of Onset | 1 | 2006 | 3343 | 0.040 |
Why?
|
| Stomatitis | 1 | 2002 | 270 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 2 | 2012 | 190 | 0.040 |
Why?
|
| Vegetables | 1 | 2004 | 1200 | 0.040 |
Why?
|
| Melphalan | 1 | 2020 | 425 | 0.040 |
Why?
|
| Health Status Indicators | 1 | 2004 | 966 | 0.040 |
Why?
|
| Immunotoxins | 1 | 1999 | 177 | 0.040 |
Why?
|
| Naphthalimides | 2 | 2015 | 22 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2007 | 3446 | 0.040 |
Why?
|
| Secondary Prevention | 4 | 2011 | 1472 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2020 | 371 | 0.040 |
Why?
|
| Environmental Exposure | 2 | 2004 | 4543 | 0.040 |
Why?
|
| Random Allocation | 3 | 2016 | 2395 | 0.040 |
Why?
|
| HLA-DQ Antigens | 1 | 1999 | 190 | 0.040 |
Why?
|
| Radiotherapy | 3 | 2013 | 1494 | 0.040 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2001 | 657 | 0.040 |
Why?
|
| Chemokine CXCL10 | 2 | 2011 | 310 | 0.040 |
Why?
|
| Protease Inhibitors | 1 | 2002 | 746 | 0.040 |
Why?
|
| DNA Helicases | 1 | 2004 | 852 | 0.040 |
Why?
|
| Radiation, Ionizing | 2 | 2012 | 249 | 0.040 |
Why?
|
| Heart | 1 | 2012 | 4414 | 0.040 |
Why?
|
| Flavonoids | 1 | 2002 | 448 | 0.040 |
Why?
|
| Pharmacogenetics | 2 | 2015 | 682 | 0.040 |
Why?
|
| Papillomaviridae | 2 | 2013 | 1141 | 0.040 |
Why?
|
| Pilot Projects | 9 | 2010 | 8733 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 36532 | 0.040 |
Why?
|
| Cytokines | 5 | 2018 | 7421 | 0.040 |
Why?
|
| Cullin Proteins | 1 | 1999 | 178 | 0.040 |
Why?
|
| Pandemics | 3 | 2024 | 8701 | 0.040 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2020 | 303 | 0.040 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2018 | 95 | 0.040 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2020 | 308 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2020 | 10383 | 0.040 |
Why?
|
| Cryopreservation | 1 | 2003 | 728 | 0.040 |
Why?
|
| Hyperglycemia | 1 | 2007 | 1393 | 0.040 |
Why?
|
| Receptors, CXCR4 | 2 | 2019 | 728 | 0.040 |
Why?
|
| Glycine | 1 | 2022 | 672 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2004 | 906 | 0.040 |
Why?
|
| von Hippel-Lindau Disease | 1 | 1999 | 154 | 0.040 |
Why?
|
| Ukraine | 1 | 2018 | 151 | 0.040 |
Why?
|
| Mice, 129 Strain | 1 | 2019 | 369 | 0.040 |
Why?
|
| Histocompatibility | 1 | 1999 | 327 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 4 | 2011 | 6220 | 0.040 |
Why?
|
| Choice Behavior | 1 | 2004 | 844 | 0.040 |
Why?
|
| Genes, Retinoblastoma | 1 | 2018 | 125 | 0.040 |
Why?
|
| Myocardial Contraction | 2 | 2015 | 1515 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2005 | 2845 | 0.040 |
Why?
|
| Pyrroles | 2 | 2015 | 1119 | 0.040 |
Why?
|
| Chronic Disease | 5 | 2024 | 9347 | 0.040 |
Why?
|
| Canada | 2 | 2015 | 2119 | 0.040 |
Why?
|
| Blood Component Removal | 3 | 2004 | 124 | 0.040 |
Why?
|
| Community Health Services | 1 | 2003 | 657 | 0.040 |
Why?
|
| Prevotella | 1 | 2017 | 81 | 0.040 |
Why?
|
| Nuclear Family | 1 | 1999 | 311 | 0.040 |
Why?
|
| Carotid Arteries | 2 | 2012 | 929 | 0.040 |
Why?
|
| Amino Acid Substitution | 2 | 2013 | 1740 | 0.040 |
Why?
|
| Calreticulin | 1 | 2018 | 111 | 0.040 |
Why?
|
| Species Specificity | 2 | 2014 | 2406 | 0.040 |
Why?
|
| Transplantation, Isogeneic | 2 | 2012 | 251 | 0.040 |
Why?
|
| Syndrome | 2 | 2015 | 3271 | 0.040 |
Why?
|
| HT29 Cells | 1 | 2017 | 187 | 0.040 |
Why?
|
| Phospholipase C gamma | 1 | 2017 | 130 | 0.040 |
Why?
|
| Severity of Illness Index | 4 | 2020 | 15880 | 0.040 |
Why?
|
| Homozygote | 3 | 2015 | 1775 | 0.040 |
Why?
|
| Heterozygote | 3 | 2015 | 2794 | 0.040 |
Why?
|
| Retroviridae | 3 | 2005 | 847 | 0.040 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2000 | 1145 | 0.040 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2018 | 157 | 0.040 |
Why?
|
| Hydrolases | 1 | 2018 | 146 | 0.040 |
Why?
|
| Histone Demethylases | 1 | 2020 | 328 | 0.030 |
Why?
|
| Automation | 1 | 2020 | 585 | 0.030 |
Why?
|
| Polydeoxyribonucleotides | 1 | 1998 | 136 | 0.030 |
Why?
|
| Imides | 1 | 1997 | 15 | 0.030 |
Why?
|
| Bacteroides | 1 | 2017 | 165 | 0.030 |
Why?
|
| Pheochromocytoma | 1 | 1999 | 323 | 0.030 |
Why?
|
| Genetic Testing | 3 | 1999 | 3595 | 0.030 |
Why?
|
| Inflammasomes | 1 | 2022 | 543 | 0.030 |
Why?
|
| Ligands | 2 | 2018 | 3273 | 0.030 |
Why?
|
| Progesterone | 1 | 2001 | 752 | 0.030 |
Why?
|
| Models, Genetic | 3 | 2007 | 3448 | 0.030 |
Why?
|
| Protein Stability | 1 | 2019 | 577 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2021 | 1072 | 0.030 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2020 | 456 | 0.030 |
Why?
|
| DNA Repair Enzymes | 1 | 2018 | 342 | 0.030 |
Why?
|
| Heart Septal Defects | 1 | 2018 | 191 | 0.030 |
Why?
|
| Response Elements | 1 | 2018 | 307 | 0.030 |
Why?
|
| Heparin | 2 | 2021 | 1630 | 0.030 |
Why?
|
| Forearm | 1 | 2019 | 427 | 0.030 |
Why?
|
| Autophagy | 2 | 2018 | 1351 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2022 | 769 | 0.030 |
Why?
|
| Frail Elderly | 1 | 2022 | 785 | 0.030 |
Why?
|
| Injections, Subcutaneous | 2 | 2010 | 682 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2022 | 15651 | 0.030 |
Why?
|
| Family Health | 2 | 2012 | 1253 | 0.030 |
Why?
|
| Cytokine Receptor gp130 | 1 | 2016 | 66 | 0.030 |
Why?
|
| Genes, Dominant | 1 | 2019 | 856 | 0.030 |
Why?
|
| Immune System | 2 | 2016 | 799 | 0.030 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 431 | 0.030 |
Why?
|
| Tandem Repeat Sequences | 2 | 2011 | 184 | 0.030 |
Why?
|
| Tissue Distribution | 2 | 2013 | 2266 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2022 | 1028 | 0.030 |
Why?
|
| Megestrol | 1 | 1996 | 9 | 0.030 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2012 | 3675 | 0.030 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 1998 | 221 | 0.030 |
Why?
|
| Stromal Cells | 2 | 2012 | 1329 | 0.030 |
Why?
|
| Uric Acid | 1 | 2022 | 809 | 0.030 |
Why?
|
| Health Behavior | 1 | 2008 | 2650 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2018 | 370 | 0.030 |
Why?
|
| Air Pollution, Indoor | 1 | 2004 | 931 | 0.030 |
Why?
|
| Chromatography, Thin Layer | 1 | 2016 | 211 | 0.030 |
Why?
|
| Acyl Coenzyme A | 1 | 2016 | 57 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2018 | 720 | 0.030 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1998 | 894 | 0.030 |
Why?
|
| Histiocytic Sarcoma | 1 | 2016 | 41 | 0.030 |
Why?
|
| Immunity, Humoral | 2 | 2010 | 605 | 0.030 |
Why?
|
| Lung | 2 | 2008 | 10033 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2007 | 3606 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 1761 | 0.030 |
Why?
|
| Stroke Volume | 2 | 2023 | 5596 | 0.030 |
Why?
|
| Vomiting | 2 | 2012 | 647 | 0.030 |
Why?
|
| RNA Transport | 1 | 2015 | 42 | 0.030 |
Why?
|
| Haemophilus Vaccines | 1 | 1995 | 70 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 2019 | 1478 | 0.030 |
Why?
|
| Trisomy | 2 | 2014 | 259 | 0.030 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2017 | 197 | 0.030 |
Why?
|
| Life Tables | 4 | 1998 | 363 | 0.030 |
Why?
|
| Oxidation-Reduction | 2 | 2016 | 2218 | 0.030 |
Why?
|
| Ketoglutaric Acids | 1 | 2016 | 75 | 0.030 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 14749 | 0.030 |
Why?
|
| Marital Status | 1 | 2017 | 426 | 0.030 |
Why?
|
| Lymphocyte Count | 2 | 2013 | 790 | 0.030 |
Why?
|
| Electron Transport Complex IV | 1 | 2016 | 188 | 0.030 |
Why?
|
| Databases, Factual | 3 | 2017 | 8067 | 0.030 |
Why?
|
| Immunoglobulin mu-Chains | 1 | 2015 | 62 | 0.030 |
Why?
|
| In Situ Hybridization | 2 | 2011 | 1886 | 0.030 |
Why?
|
| Stomach Neoplasms | 2 | 1996 | 1471 | 0.030 |
Why?
|
| Biological Products | 1 | 2024 | 942 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 1999 | 1162 | 0.030 |
Why?
|
| Inflammation | 2 | 2015 | 10850 | 0.030 |
Why?
|
| Graft Survival | 5 | 2008 | 3890 | 0.030 |
Why?
|
| Ribonucleoprotein, U2 Small Nuclear | 1 | 2014 | 19 | 0.030 |
Why?
|
| beta-Globins | 1 | 2015 | 112 | 0.030 |
Why?
|
| Cell Transdifferentiation | 1 | 2016 | 186 | 0.030 |
Why?
|
| Paraffin | 1 | 2014 | 36 | 0.030 |
Why?
|
| Cytosine | 1 | 2016 | 213 | 0.030 |
Why?
|
| Antisickling Agents | 1 | 2015 | 72 | 0.030 |
Why?
|
| Research Personnel | 1 | 2020 | 590 | 0.030 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2017 | 166 | 0.030 |
Why?
|
| GTPase-Activating Proteins | 1 | 2018 | 465 | 0.030 |
Why?
|
| Algorithms | 4 | 2021 | 14071 | 0.030 |
Why?
|
| Estrogens | 1 | 2001 | 1529 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2011 | 20660 | 0.030 |
Why?
|
| RNA | 1 | 2004 | 2717 | 0.030 |
Why?
|
| Electron Transport Complex I | 1 | 2016 | 151 | 0.030 |
Why?
|
| Antibodies | 1 | 2022 | 2417 | 0.030 |
Why?
|
| rap GTP-Binding Proteins | 1 | 2014 | 24 | 0.030 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2003 | 942 | 0.030 |
Why?
|
| Immunoglobulin E | 1 | 2001 | 1481 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 416 | 0.030 |
Why?
|
| Respiratory Tract Diseases | 1 | 2000 | 744 | 0.030 |
Why?
|
| Immunity, Mucosal | 1 | 2018 | 498 | 0.030 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 1996 | 274 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 2006 | 2084 | 0.030 |
Why?
|
| Cell Division | 4 | 2004 | 4475 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2019 | 996 | 0.030 |
Why?
|
| Reference Values | 3 | 2011 | 4908 | 0.030 |
Why?
|
| Antitubercular Agents | 1 | 2003 | 1384 | 0.030 |
Why?
|
| Automation, Laboratory | 1 | 2014 | 102 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2006 | 314 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 2015 | 552 | 0.030 |
Why?
|
| Antigens, Nuclear | 1 | 2014 | 182 | 0.030 |
Why?
|
| Transcription Initiation Site | 1 | 2014 | 190 | 0.030 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 2014 | 84 | 0.030 |
Why?
|
| Thiophenes | 1 | 2018 | 569 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2014 | 76 | 0.030 |
Why?
|
| Core Binding Factor beta Subunit | 1 | 2013 | 42 | 0.030 |
Why?
|
| Vaccines, Conjugate | 1 | 1995 | 334 | 0.030 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2014 | 117 | 0.030 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1999 | 730 | 0.030 |
Why?
|
| Bone Marrow Examination | 2 | 2005 | 155 | 0.030 |
Why?
|
| Injections, Intravenous | 2 | 2010 | 1377 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2007 | 3426 | 0.030 |
Why?
|
| Toll-Like Receptor 6 | 1 | 2013 | 29 | 0.030 |
Why?
|
| Cell Death | 1 | 2019 | 1679 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2011 | 1167 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2014 | 301 | 0.030 |
Why?
|
| Receptors, Pituitary Hormone | 1 | 2013 | 29 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2014 | 244 | 0.030 |
Why?
|
| Retreatment | 1 | 2015 | 598 | 0.030 |
Why?
|
| Logistic Models | 4 | 2014 | 13266 | 0.030 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 1994 | 237 | 0.030 |
Why?
|
| Toll-Like Receptor 1 | 1 | 2013 | 48 | 0.030 |
Why?
|
| Bacterial Vaccines | 1 | 1995 | 400 | 0.030 |
Why?
|
| Ultrasonography, Prenatal | 2 | 1992 | 1774 | 0.030 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 1995 | 307 | 0.030 |
Why?
|
| Feces | 1 | 2020 | 1504 | 0.030 |
Why?
|
| Stem Cell Niche | 1 | 2016 | 346 | 0.030 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2013 | 124 | 0.030 |
Why?
|
| Tyrphostins | 1 | 2013 | 63 | 0.030 |
Why?
|
| Fenofibrate | 1 | 2013 | 87 | 0.030 |
Why?
|
| Massachusetts | 3 | 2016 | 8871 | 0.030 |
Why?
|
| Gene Order | 1 | 2013 | 164 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2014 | 352 | 0.030 |
Why?
|
| Goserelin | 1 | 1993 | 126 | 0.030 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2015 | 394 | 0.030 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 1994 | 327 | 0.030 |
Why?
|
| Carcinoma, Small Cell | 1 | 1995 | 420 | 0.030 |
Why?
|
| Diet | 3 | 2007 | 8086 | 0.030 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 1995 | 403 | 0.030 |
Why?
|
| Janus Kinase 3 | 1 | 2013 | 75 | 0.030 |
Why?
|
| Taxoids | 1 | 1996 | 665 | 0.030 |
Why?
|
| Interferon Type I | 1 | 1997 | 567 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 3 | 2003 | 813 | 0.030 |
Why?
|
| Blood Coagulation | 1 | 2019 | 1166 | 0.030 |
Why?
|
| Polysaccharides, Bacterial | 1 | 1995 | 576 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2013 | 312 | 0.030 |
Why?
|
| Nitriles | 1 | 2018 | 982 | 0.030 |
Why?
|
| Metalloproteins | 2 | 2004 | 98 | 0.030 |
Why?
|
| Europe | 1 | 2019 | 3423 | 0.030 |
Why?
|
| Benchmarking | 1 | 2019 | 1052 | 0.030 |
Why?
|
| Limulus Test | 1 | 1992 | 19 | 0.030 |
Why?
|
| Iron Overload | 1 | 2015 | 245 | 0.030 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2018 | 722 | 0.030 |
Why?
|
| Antibody Formation | 2 | 2010 | 1391 | 0.020 |
Why?
|
| Ploidies | 1 | 2013 | 287 | 0.020 |
Why?
|
| Watchful Waiting | 1 | 2016 | 493 | 0.020 |
Why?
|
| HLA-B Antigens | 1 | 2013 | 329 | 0.020 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2012 | 94 | 0.020 |
Why?
|
| Ribonucleoproteins | 1 | 2014 | 359 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2019 | 1470 | 0.020 |
Why?
|
| Overweight | 1 | 2023 | 2443 | 0.020 |
Why?
|
| Organisms, Genetically Modified | 1 | 2012 | 63 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2014 | 780 | 0.020 |
Why?
|
| Dosage Compensation, Genetic | 1 | 2013 | 209 | 0.020 |
Why?
|
| F-Box Proteins | 1 | 2013 | 199 | 0.020 |
Why?
|
| Chromosome Duplication | 1 | 2012 | 79 | 0.020 |
Why?
|
| Genes, p16 | 1 | 2012 | 157 | 0.020 |
Why?
|
| Second-Look Surgery | 1 | 2011 | 27 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 479 | 0.020 |
Why?
|
| Cyclosporine | 1 | 1994 | 778 | 0.020 |
Why?
|
| Cluster Analysis | 2 | 2012 | 2720 | 0.020 |
Why?
|
| Lymphocyte Subsets | 1 | 2013 | 315 | 0.020 |
Why?
|
| E2F Transcription Factors | 1 | 2012 | 269 | 0.020 |
Why?
|
| Laparotomy | 1 | 1994 | 460 | 0.020 |
Why?
|
| Cryoultramicrotomy | 1 | 2011 | 16 | 0.020 |
Why?
|
| Occupational Diseases | 1 | 2000 | 1456 | 0.020 |
Why?
|
| Cyclins | 2 | 2006 | 598 | 0.020 |
Why?
|
| Transcription Factor RelA | 1 | 2013 | 252 | 0.020 |
Why?
|
| Intestine, Small | 1 | 2018 | 1214 | 0.020 |
Why?
|
| Registries | 2 | 2020 | 8297 | 0.020 |
Why?
|
| Virus Integration | 1 | 2013 | 304 | 0.020 |
Why?
|
| Mitotic Index | 1 | 2011 | 159 | 0.020 |
Why?
|
| Medically Uninsured | 1 | 2017 | 838 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2012 | 162 | 0.020 |
Why?
|
| Procarbazine | 2 | 2004 | 172 | 0.020 |
Why?
|
| Motor Neurons | 1 | 2016 | 869 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2012 | 272 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2016 | 1091 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2013 | 507 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2012 | 305 | 0.020 |
Why?
|
| Methylation | 1 | 2014 | 1073 | 0.020 |
Why?
|
| Antigens, CD7 | 2 | 2001 | 30 | 0.020 |
Why?
|
| Cause of Death | 3 | 2013 | 3708 | 0.020 |
Why?
|
| Equipment Design | 1 | 2019 | 3481 | 0.020 |
Why?
|
| Radiation Chimera | 1 | 2011 | 216 | 0.020 |
Why?
|
| Radiotherapy Dosage | 3 | 2004 | 2865 | 0.020 |
Why?
|
| Cell-Derived Microparticles | 1 | 2012 | 160 | 0.020 |
Why?
|
| Pedigree | 2 | 2012 | 4526 | 0.020 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2013 | 348 | 0.020 |
Why?
|
| Caspase 3 | 2 | 2004 | 731 | 0.020 |
Why?
|
| Microsatellite Repeats | 2 | 2005 | 784 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 2 | 2010 | 2627 | 0.020 |
Why?
|
| Ankle Brachial Index | 1 | 2011 | 166 | 0.020 |
Why?
|
| Protein Kinases | 1 | 2018 | 1611 | 0.020 |
Why?
|
| Immunocompetence | 1 | 2011 | 138 | 0.020 |
Why?
|
| p-Methoxy-N-methylphenethylamine | 1 | 2010 | 41 | 0.020 |
Why?
|
| Protein Transport | 1 | 2016 | 1938 | 0.020 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2013 | 385 | 0.020 |
Why?
|
| Age Determination by Skeleton | 1 | 2011 | 124 | 0.020 |
Why?
|
| Mesna | 2 | 2004 | 62 | 0.020 |
Why?
|
| Ketotifen | 1 | 2010 | 24 | 0.020 |
Why?
|
| Glycolysis | 1 | 2015 | 838 | 0.020 |
Why?
|
| Amino Acids | 1 | 2017 | 1709 | 0.020 |
Why?
|
| Pain | 2 | 2023 | 5077 | 0.020 |
Why?
|
| Inverted Repeat Sequences | 1 | 2010 | 59 | 0.020 |
Why?
|
| Carrier Proteins | 2 | 2004 | 4913 | 0.020 |
Why?
|
| Hemolytic-Uremic Syndrome | 1 | 1991 | 105 | 0.020 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2012 | 428 | 0.020 |
Why?
|
| Pulsatile Flow | 1 | 2011 | 318 | 0.020 |
Why?
|
| Receptors, Fc | 1 | 2014 | 536 | 0.020 |
Why?
|
| Insulin | 1 | 2005 | 6599 | 0.020 |
Why?
|
| Dimerization | 2 | 2006 | 880 | 0.020 |
Why?
|
| Mediastinum | 1 | 2012 | 271 | 0.020 |
Why?
|
| Erythroid Precursor Cells | 1 | 2011 | 211 | 0.020 |
Why?
|
| Oligonucleotide Probes | 1 | 2010 | 417 | 0.020 |
Why?
|
| Cell Transformation, Viral | 1 | 2012 | 527 | 0.020 |
Why?
|
| Cell Aggregation | 1 | 2010 | 238 | 0.020 |
Why?
|
| Autocrine Communication | 1 | 2011 | 167 | 0.020 |
Why?
|
| Angiopoietin-1 | 1 | 2010 | 132 | 0.020 |
Why?
|
| Models, Animal | 1 | 2017 | 2120 | 0.020 |
Why?
|
| Twins | 1 | 2012 | 341 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2012 | 629 | 0.020 |
Why?
|
| Nucleosomes | 1 | 2014 | 494 | 0.020 |
Why?
|
| Caspases | 2 | 2004 | 880 | 0.020 |
Why?
|
| Histamine H1 Antagonists | 1 | 2010 | 100 | 0.020 |
Why?
|
| T-Lymphocyte Subsets | 1 | 1998 | 1811 | 0.020 |
Why?
|
| Seasons | 2 | 2007 | 1524 | 0.020 |
Why?
|
| Occupational Exposure | 3 | 2008 | 1805 | 0.020 |
Why?
|
| Receptor, TIE-2 | 1 | 2010 | 183 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2017 | 1308 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2013 | 700 | 0.020 |
Why?
|
| Hypersensitivity, Delayed | 2 | 2003 | 490 | 0.020 |
Why?
|
| Codon | 2 | 2004 | 595 | 0.020 |
Why?
|
| Caspase 8 | 1 | 2010 | 198 | 0.020 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2014 | 302 | 0.020 |
Why?
|
| Anemia, Diamond-Blackfan | 1 | 2011 | 147 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2004 | 3529 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 1701 | 0.020 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 2 | 2001 | 94 | 0.020 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2010 | 71 | 0.020 |
Why?
|
| Air Pollutants | 1 | 2004 | 2923 | 0.020 |
Why?
|
| Clinical Trials as Topic | 5 | 2010 | 8041 | 0.020 |
Why?
|
| DNA, Complementary | 2 | 2004 | 1984 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2017 | 1727 | 0.020 |
Why?
|
| Observer Variation | 1 | 2016 | 2615 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2010 | 573 | 0.020 |
Why?
|
| DNA Probes | 2 | 2003 | 541 | 0.020 |
Why?
|
| Endotoxins | 1 | 1992 | 516 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2017 | 1402 | 0.020 |
Why?
|
| Growth Plate | 1 | 2011 | 273 | 0.020 |
Why?
|
| Angiopoietin-2 | 1 | 2010 | 187 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2012 | 898 | 0.020 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2011 | 357 | 0.020 |
Why?
|
| Educational Status | 1 | 2017 | 2513 | 0.020 |
Why?
|
| RNA-Binding Proteins | 2 | 2009 | 1874 | 0.020 |
Why?
|
| Isoxazoles | 1 | 2011 | 234 | 0.020 |
Why?
|
| Cell Fusion | 1 | 2010 | 295 | 0.020 |
Why?
|
| Muscle, Skeletal | 2 | 2019 | 4959 | 0.020 |
Why?
|
| Genetic Counseling | 1 | 2013 | 634 | 0.020 |
Why?
|
| U937 Cells | 1 | 2009 | 259 | 0.020 |
Why?
|
| Puerto Rico | 1 | 2010 | 381 | 0.020 |
Why?
|
| AIDS-Related Complex | 1 | 1989 | 107 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 3602 | 0.020 |
Why?
|
| Calgranulin A | 1 | 2009 | 80 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 1998 | 1587 | 0.020 |
Why?
|
| Zinc Fingers | 1 | 2011 | 576 | 0.020 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2002 | 227 | 0.020 |
Why?
|
| Hemostasis | 1 | 2012 | 467 | 0.020 |
Why?
|
| Cholangiocarcinoma | 1 | 1995 | 578 | 0.020 |
Why?
|
| Bile Duct Neoplasms | 1 | 1995 | 626 | 0.020 |
Why?
|
| Renal Insufficiency | 1 | 2015 | 804 | 0.020 |
Why?
|
| Immunodominant Epitopes | 1 | 2010 | 244 | 0.020 |
Why?
|
| Humerus | 1 | 1991 | 272 | 0.020 |
Why?
|
| Peroxidase | 2 | 2003 | 606 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 2010 | 415 | 0.020 |
Why?
|
| Indazoles | 1 | 1990 | 303 | 0.020 |
Why?
|
| Neuropsychological Tests | 2 | 2015 | 7122 | 0.020 |
Why?
|
| Transplantation, Heterologous | 2 | 2012 | 2394 | 0.020 |
Why?
|
| Telomeric Repeat Binding Protein 2 | 1 | 2008 | 20 | 0.020 |
Why?
|
| Fibrinolytic Agents | 1 | 1998 | 2080 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2019 | 2858 | 0.020 |
Why?
|
| Boston | 2 | 2015 | 9338 | 0.020 |
Why?
|
| Drugs, Investigational | 1 | 1990 | 211 | 0.020 |
Why?
|
| Antigens, CD20 | 2 | 2003 | 198 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2011 | 827 | 0.020 |
Why?
|
| Quinolines | 1 | 2014 | 769 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2019 | 2892 | 0.020 |
Why?
|
| Income | 1 | 2017 | 1874 | 0.020 |
Why?
|
| Antigens, Viral | 1 | 2012 | 995 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2012 | 863 | 0.020 |
Why?
|
| Nucleic Acids | 1 | 2011 | 193 | 0.020 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2010 | 245 | 0.020 |
Why?
|
| Rheumatic Diseases | 1 | 2015 | 622 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2012 | 561 | 0.020 |
Why?
|
| Social Class | 1 | 2017 | 2007 | 0.020 |
Why?
|
| Welding | 1 | 2008 | 89 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2010 | 647 | 0.020 |
Why?
|
| Self-Examination | 1 | 2008 | 72 | 0.020 |
Why?
|
| Imidazoles | 1 | 2014 | 1162 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2011 | 1381 | 0.020 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 1994 | 790 | 0.020 |
Why?
|
| Fetal Hemoglobin | 1 | 2010 | 348 | 0.020 |
Why?
|
| Placebos | 2 | 2002 | 1659 | 0.020 |
Why?
|
| Cross-Priming | 1 | 2008 | 75 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2010 | 607 | 0.020 |
Why?
|
| Multiple Organ Failure | 2 | 2002 | 390 | 0.020 |
Why?
|
| Radiography, Abdominal | 1 | 2011 | 544 | 0.020 |
Why?
|
| Receptor-Like Protein Tyrosine Phosphatases, Class 3 | 1 | 2007 | 25 | 0.020 |
Why?
|
| Attachment Sites, Microbiological | 1 | 2007 | 26 | 0.020 |
Why?
|
| Bone Remodeling | 1 | 2011 | 577 | 0.020 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2002 | 284 | 0.020 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 2 | 2002 | 318 | 0.020 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2009 | 180 | 0.020 |
Why?
|
| Developing Countries | 2 | 2015 | 2911 | 0.020 |
Why?
|
| Blood Group Incompatibility | 1 | 2008 | 134 | 0.020 |
Why?
|
| Gills | 1 | 2007 | 22 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2013 | 1183 | 0.020 |
Why?
|
| Cell Size | 1 | 2009 | 625 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2008 | 287 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2010 | 3513 | 0.020 |
Why?
|
| Femoral Artery | 1 | 2011 | 811 | 0.020 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2011 | 548 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2011 | 1336 | 0.020 |
Why?
|
| Fibrinogen | 1 | 2010 | 895 | 0.020 |
Why?
|
| Artificial Intelligence | 1 | 2002 | 2659 | 0.020 |
Why?
|
| Living Donors | 1 | 2011 | 645 | 0.020 |
Why?
|
| Fetal Diseases | 1 | 1992 | 914 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-ret | 2 | 1999 | 228 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2016 | 3633 | 0.020 |
Why?
|
| Injections, Spinal | 1 | 2007 | 310 | 0.020 |
Why?
|
| Epigenomics | 1 | 2012 | 959 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2013 | 2587 | 0.020 |
Why?
|
| Filgrastim | 2 | 1998 | 131 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2010 | 618 | 0.020 |
Why?
|
| Multigene Family | 1 | 2010 | 1080 | 0.020 |
Why?
|
| Anthropometry | 1 | 2011 | 1338 | 0.020 |
Why?
|
| Graft Rejection | 2 | 2011 | 4499 | 0.020 |
Why?
|
| Microinjections | 1 | 2007 | 320 | 0.020 |
Why?
|
| Tacrolimus Binding Protein 1A | 1 | 2006 | 40 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2010 | 2171 | 0.020 |
Why?
|
| Cyclin D2 | 1 | 2006 | 97 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2007 | 1306 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2010 | 1347 | 0.020 |
Why?
|
| Contrast Media | 1 | 2019 | 5329 | 0.020 |
Why?
|
| Pregnancy | 4 | 2020 | 30258 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2012 | 3067 | 0.020 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2016 | 1663 | 0.020 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 1993 | 920 | 0.020 |
Why?
|
| Proteome | 1 | 2016 | 1899 | 0.020 |
Why?
|
| Half-Life | 1 | 2007 | 644 | 0.020 |
Why?
|
| Receptors, Erythropoietin | 1 | 2006 | 145 | 0.020 |
Why?
|
| Disease Management | 1 | 2016 | 2535 | 0.020 |
Why?
|
| Inhalation Exposure | 1 | 2008 | 432 | 0.020 |
Why?
|
| Thymopoietins | 1 | 2005 | 10 | 0.020 |
Why?
|
| Causality | 1 | 2012 | 1248 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2013 | 1241 | 0.020 |
Why?
|
| Diarrhea | 1 | 2012 | 1316 | 0.020 |
Why?
|
| Eosinophils | 2 | 2002 | 945 | 0.020 |
Why?
|
| Cyclin B | 1 | 2005 | 104 | 0.020 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2009 | 618 | 0.020 |
Why?
|
| Employment | 1 | 2012 | 1106 | 0.020 |
Why?
|
| Genetic Engineering | 2 | 2003 | 933 | 0.020 |
Why?
|
| Regression Analysis | 3 | 2003 | 6321 | 0.020 |
Why?
|
| STAT5 Transcription Factor | 1 | 2006 | 269 | 0.020 |
Why?
|
| Endostatins | 1 | 2005 | 167 | 0.020 |
Why?
|
| Mucin-1 | 1 | 2010 | 531 | 0.020 |
Why?
|
| Poverty | 1 | 2017 | 2714 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2011 | 1707 | 0.020 |
Why?
|
| Molecular Chaperones | 1 | 2010 | 762 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2013 | 1792 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2023 | 5506 | 0.010 |
Why?
|
| Age Distribution | 1 | 2011 | 2858 | 0.010 |
Why?
|
| Adenosine Deaminase | 1 | 2007 | 251 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 2011 | 1441 | 0.010 |
Why?
|
| Body Height | 1 | 2011 | 1562 | 0.010 |
Why?
|
| Thrombospondins | 1 | 2005 | 197 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2015 | 2590 | 0.010 |
Why?
|
| Premenopause | 1 | 2009 | 1037 | 0.010 |
Why?
|
| S Phase | 1 | 2006 | 424 | 0.010 |
Why?
|
| Binding Sites | 1 | 2013 | 6001 | 0.010 |
Why?
|
| G1 Phase | 1 | 2006 | 403 | 0.010 |
Why?
|
| Mycoplasma | 1 | 2005 | 144 | 0.010 |
Why?
|
| Software | 1 | 1999 | 4462 | 0.010 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2004 | 42 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2021 | 8927 | 0.010 |
Why?
|
| Femur | 1 | 1991 | 1310 | 0.010 |
Why?
|
| bcl-Associated Death Protein | 1 | 2004 | 102 | 0.010 |
Why?
|
| Ventricular Remodeling | 1 | 2012 | 1272 | 0.010 |
Why?
|
| Immunomagnetic Separation | 1 | 2004 | 78 | 0.010 |
Why?
|
| Diagnosis, Differential | 3 | 2008 | 12976 | 0.010 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2013 | 1892 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2021 | 4873 | 0.010 |
Why?
|
| Caspase 9 | 1 | 2004 | 184 | 0.010 |
Why?
|
| Pancytopenia | 1 | 2005 | 101 | 0.010 |
Why?
|
| Breast | 1 | 2013 | 1946 | 0.010 |
Why?
|
| Feedback, Physiological | 1 | 2006 | 480 | 0.010 |
Why?
|
| VDJ Recombinases | 1 | 2004 | 84 | 0.010 |
Why?
|
| Tennessee | 1 | 2004 | 123 | 0.010 |
Why?
|
| Cholesterol | 1 | 2013 | 2898 | 0.010 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2004 | 84 | 0.010 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2005 | 461 | 0.010 |
Why?
|
| Models, Immunological | 1 | 2006 | 517 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2004 | 425 | 0.010 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2004 | 105 | 0.010 |
Why?
|
| Mortality | 2 | 2005 | 2904 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2011 | 2194 | 0.010 |
Why?
|
| Solutions | 1 | 2004 | 403 | 0.010 |
Why?
|
| Uterine Diseases | 1 | 2004 | 108 | 0.010 |
Why?
|
| Centromere | 1 | 2004 | 213 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 2003 | 261 | 0.010 |
Why?
|
| Internet | 1 | 2016 | 3106 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2004 | 185 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 5369 | 0.010 |
Why?
|
| TNF Receptor-Associated Factor 1 | 1 | 2003 | 48 | 0.010 |
Why?
|
| Drug Evaluation | 2 | 1998 | 641 | 0.010 |
Why?
|
| Medicaid | 1 | 2017 | 2831 | 0.010 |
Why?
|
| Codon, Nonsense | 1 | 2005 | 288 | 0.010 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 2780 | 0.010 |
Why?
|
| Fluorescence | 1 | 2006 | 753 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 2004 | 405 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2005 | 594 | 0.010 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2004 | 229 | 0.010 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2003 | 128 | 0.010 |
Why?
|
| Perforin | 1 | 2003 | 166 | 0.010 |
Why?
|
| Prevalence | 2 | 2012 | 15839 | 0.010 |
Why?
|
| Neovascularization, Physiologic | 1 | 2010 | 1375 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 1657 | 0.010 |
Why?
|
| Chromosome Disorders | 2 | 1998 | 498 | 0.010 |
Why?
|
| Receptor, erbB-2 | 1 | 2013 | 2593 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 2007 | 1525 | 0.010 |
Why?
|
| Protein Engineering | 1 | 2006 | 550 | 0.010 |
Why?
|
| Phylogeny | 1 | 2010 | 2832 | 0.010 |
Why?
|
| Sarcoma | 1 | 2014 | 1802 | 0.010 |
Why?
|
| Blood Proteins | 1 | 2008 | 1188 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2005 | 608 | 0.010 |
Why?
|
| Health Services | 1 | 2008 | 756 | 0.010 |
Why?
|
| RNA Stability | 1 | 2004 | 319 | 0.010 |
Why?
|
| Reproduction | 1 | 2007 | 641 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 1989 | 2352 | 0.010 |
Why?
|
| Luminescent Measurements | 1 | 2004 | 341 | 0.010 |
Why?
|
| Transfection | 2 | 2002 | 5743 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2004 | 2899 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2003 | 812 | 0.010 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 1994 | 2176 | 0.010 |
Why?
|
| Weight Gain | 1 | 2012 | 2355 | 0.010 |
Why?
|
| Annexin A5 | 1 | 2002 | 102 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2005 | 11083 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2009 | 1652 | 0.010 |
Why?
|
| Methods | 1 | 2002 | 1052 | 0.010 |
Why?
|
| Cell Transplantation | 1 | 2004 | 473 | 0.010 |
Why?
|
| Leucovorin | 1 | 2004 | 641 | 0.010 |
Why?
|
| Self Disclosure | 1 | 2003 | 248 | 0.010 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2004 | 484 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 2011 | 2324 | 0.010 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2003 | 431 | 0.010 |
Why?
|
| tRNA Methyltransferases | 1 | 2002 | 50 | 0.010 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2002 | 178 | 0.010 |
Why?
|
| Data Collection | 1 | 2011 | 3318 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 2002 | 310 | 0.010 |
Why?
|
| Cell Membrane Permeability | 1 | 2003 | 562 | 0.010 |
Why?
|
| Nausea | 1 | 2005 | 680 | 0.010 |
Why?
|
| Asthma | 1 | 2001 | 6270 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 4353 | 0.010 |
Why?
|
| Drug Therapy | 1 | 2005 | 504 | 0.010 |
Why?
|
| Papillomavirus Infections | 1 | 2013 | 1640 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2007 | 2060 | 0.010 |
Why?
|
| Dendritic Cells, Follicular | 1 | 2001 | 50 | 0.010 |
Why?
|
| Physical Examination | 1 | 2008 | 1266 | 0.010 |
Why?
|
| Kidney | 2 | 2007 | 7066 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2010 | 2024 | 0.010 |
Why?
|
| Melatonin | 1 | 2007 | 674 | 0.010 |
Why?
|
| Radiography | 1 | 2012 | 6919 | 0.010 |
Why?
|
| ADP-ribosyl Cyclase | 1 | 2000 | 38 | 0.010 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2011 | 2054 | 0.010 |
Why?
|
| Interleukin-13 | 1 | 2003 | 388 | 0.010 |
Why?
|
| Obesity | 1 | 2023 | 13075 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2011 | 3222 | 0.010 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2002 | 304 | 0.010 |
Why?
|
| Chemokines | 1 | 2005 | 956 | 0.010 |
Why?
|
| Alkaloids | 1 | 2002 | 190 | 0.010 |
Why?
|
| NAD+ Nucleosidase | 1 | 2000 | 43 | 0.010 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2002 | 297 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 2008 | 1181 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2002 | 372 | 0.010 |
Why?
|
| Receptors, CCR2 | 1 | 2001 | 215 | 0.010 |
Why?
|
| Professional Competence | 1 | 2004 | 429 | 0.010 |
Why?
|
| Pyridones | 1 | 2006 | 816 | 0.010 |
Why?
|
| Nucleic Acid Conformation | 1 | 2004 | 901 | 0.010 |
Why?
|
| Longevity | 1 | 2008 | 1087 | 0.010 |
Why?
|
| Temperature | 1 | 2007 | 2226 | 0.010 |
Why?
|
| Focal Adhesion Kinase 2 | 1 | 2000 | 87 | 0.010 |
Why?
|
| Healthy Worker Effect | 1 | 2000 | 28 | 0.010 |
Why?
|
| Mitosis | 1 | 2005 | 1173 | 0.010 |
Why?
|
| Body Fluids | 1 | 2002 | 321 | 0.010 |
Why?
|
| Crystallography, X-Ray | 1 | 2005 | 1947 | 0.010 |
Why?
|
| Research Design | 1 | 2016 | 6208 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2004 | 1524 | 0.010 |
Why?
|
| Chemokines, CXC | 1 | 2001 | 416 | 0.010 |
Why?
|
| Plasmids | 1 | 2005 | 2274 | 0.010 |
Why?
|
| Th1 Cells | 1 | 2005 | 1039 | 0.010 |
Why?
|
| Decision Making | 2 | 2004 | 3965 | 0.010 |
Why?
|
| C-Reactive Protein | 1 | 2012 | 3850 | 0.010 |
Why?
|
| Cyclin D1 | 1 | 2002 | 449 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2002 | 869 | 0.010 |
Why?
|
| Immunoglobulin J Recombination Signal Sequence-Binding Protein | 1 | 2000 | 133 | 0.010 |
Why?
|
| Peru | 1 | 2003 | 887 | 0.010 |
Why?
|
| Chemokine CXCL12 | 1 | 2001 | 455 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2005 | 1075 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2005 | 1325 | 0.010 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2001 | 416 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 2007 | 1827 | 0.010 |
Why?
|
| Nose Diseases | 1 | 2000 | 79 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1999 | 325 | 0.010 |
Why?
|
| Hysterectomy | 1 | 2004 | 864 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2006 | 3750 | 0.010 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 3412 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2003 | 1092 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2007 | 1930 | 0.010 |
Why?
|
| Multiple Endocrine Neoplasia Type 2a | 1 | 1999 | 40 | 0.010 |
Why?
|
| Liver | 1 | 2015 | 7562 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2002 | 1644 | 0.010 |
Why?
|
| Fertility | 1 | 2003 | 768 | 0.010 |
Why?
|
| Receptors, Interleukin-12 | 1 | 1998 | 26 | 0.010 |
Why?
|
| Cesarean Section | 1 | 2008 | 1431 | 0.010 |
Why?
|
| Deoxycytidine | 1 | 2003 | 889 | 0.010 |
Why?
|
| Tyrosine | 1 | 2003 | 1428 | 0.010 |
Why?
|
| Quantitative Trait Loci | 1 | 2007 | 2140 | 0.010 |
Why?
|
| Microspheres | 1 | 2002 | 773 | 0.010 |
Why?
|
| Immunity | 1 | 2004 | 1002 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2013 | 3236 | 0.010 |
Why?
|
| Bone Density | 1 | 2011 | 3491 | 0.010 |
Why?
|
| Pharyngitis | 1 | 2000 | 221 | 0.010 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2002 | 660 | 0.010 |
Why?
|
| Receptors, Purinergic P1 | 1 | 1998 | 106 | 0.010 |
Why?
|
| Air Pollution | 1 | 1992 | 2380 | 0.010 |
Why?
|
| Menstrual Cycle | 1 | 2001 | 540 | 0.010 |
Why?
|
| Child Behavior | 1 | 2004 | 865 | 0.010 |
Why?
|
| Regeneration | 1 | 2007 | 1517 | 0.010 |
Why?
|
| Stem Cells | 1 | 2011 | 3540 | 0.010 |
Why?
|
| Chondroitin Sulfates | 1 | 1998 | 173 | 0.010 |
Why?
|
| Neprilysin | 1 | 2001 | 484 | 0.010 |
Why?
|
| Cerebellar Diseases | 1 | 2000 | 226 | 0.010 |
Why?
|
| WT1 Proteins | 1 | 1998 | 182 | 0.010 |
Why?
|
| Health Surveys | 1 | 2008 | 4056 | 0.010 |
Why?
|
| Radiation Oncology | 1 | 2004 | 569 | 0.010 |
Why?
|
| Thalassemia | 1 | 1998 | 267 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1998 | 848 | 0.010 |
Why?
|
| Fluoxymesterone | 1 | 1997 | 11 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2001 | 1749 | 0.010 |
Why?
|
| Graft vs Host Reaction | 1 | 1997 | 100 | 0.010 |
Why?
|
| Myocardium | 1 | 2010 | 4760 | 0.010 |
Why?
|
| Sputum | 1 | 2000 | 513 | 0.010 |
Why?
|
| Environmental Monitoring | 1 | 2004 | 1470 | 0.010 |
Why?
|
| Comorbidity | 1 | 2012 | 10563 | 0.010 |
Why?
|
| Receptors, Interleukin | 1 | 1998 | 243 | 0.010 |
Why?
|
| Parents | 1 | 2011 | 3592 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2003 | 1591 | 0.010 |
Why?
|
| Quality Control | 1 | 2000 | 837 | 0.010 |
Why?
|
| Drug Eruptions | 1 | 2000 | 335 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 2008 | 2207 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2004 | 2424 | 0.010 |
Why?
|
| Bilirubin | 1 | 1998 | 439 | 0.010 |
Why?
|
| Major Histocompatibility Complex | 1 | 1999 | 879 | 0.010 |
Why?
|
| Megestrol Acetate | 1 | 1996 | 18 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2003 | 1971 | 0.010 |
Why?
|
| Lymphoma, Large-Cell, Immunoblastic | 1 | 1995 | 25 | 0.010 |
Why?
|
| Cough | 1 | 2000 | 597 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2011 | 8532 | 0.010 |
Why?
|
| Genetics, Population | 1 | 2001 | 943 | 0.010 |
Why?
|
| Urogenital Abnormalities | 1 | 1998 | 255 | 0.010 |
Why?
|
| Respiratory Sounds | 1 | 2000 | 705 | 0.010 |
Why?
|
| Potassium | 1 | 2000 | 1311 | 0.010 |
Why?
|
| Exanthema | 1 | 2000 | 502 | 0.010 |
Why?
|
| Meningococcal Vaccines | 1 | 1995 | 96 | 0.010 |
Why?
|
| Antigens | 1 | 2000 | 1438 | 0.010 |
Why?
|
| Rats | 1 | 2011 | 23707 | 0.010 |
Why?
|
| Agranulocytosis | 1 | 1994 | 99 | 0.010 |
Why?
|
| Health Status | 1 | 2008 | 4080 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 5891 | 0.010 |
Why?
|
| Hyaluronic Acid | 1 | 1998 | 484 | 0.010 |
Why?
|
| Bacterial Capsules | 1 | 1995 | 246 | 0.010 |
Why?
|
| Cell Communication | 1 | 2002 | 1660 | 0.010 |
Why?
|
| Sodium | 1 | 2000 | 1591 | 0.010 |
Why?
|
| Medical Records | 1 | 2000 | 1409 | 0.010 |
Why?
|
| Dehydration | 1 | 1996 | 215 | 0.010 |
Why?
|
| Genetic Diseases, Inborn | 1 | 1999 | 605 | 0.010 |
Why?
|
| Hospitalization | 1 | 2014 | 10808 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1994 | 366 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2001 | 2199 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2004 | 3561 | 0.010 |
Why?
|
| Calcineurin | 1 | 1994 | 233 | 0.010 |
Why?
|
| Lymphography | 1 | 1994 | 189 | 0.010 |
Why?
|
| Interferons | 1 | 1997 | 714 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2003 | 3404 | 0.010 |
Why?
|
| Coronary Artery Disease | 1 | 2013 | 6546 | 0.010 |
Why?
|
| Astrocytoma | 1 | 1998 | 772 | 0.010 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 1996 | 409 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 1998 | 2910 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2002 | 2817 | 0.010 |
Why?
|
| Tissue Plasminogen Activator | 1 | 1998 | 1167 | 0.010 |
Why?
|
| Amniocentesis | 1 | 1992 | 116 | 0.010 |
Why?
|
| Rhinitis | 1 | 2000 | 752 | 0.010 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 1992 | 91 | 0.010 |
Why?
|
| Carboplatin | 1 | 1995 | 789 | 0.010 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2000 | 1568 | 0.010 |
Why?
|
| alpha-Fetoproteins | 1 | 1992 | 226 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2003 | 2778 | 0.010 |
Why?
|
| Mitolactol | 1 | 1991 | 13 | 0.010 |
Why?
|
| Thiotepa | 1 | 1991 | 66 | 0.010 |
Why?
|
| Follicle Stimulating Hormone | 1 | 1993 | 731 | 0.010 |
Why?
|
| Physician-Patient Relations | 1 | 2004 | 3278 | 0.010 |
Why?
|
| Axilla | 1 | 1993 | 615 | 0.010 |
Why?
|
| Erythrocytes | 1 | 2000 | 2395 | 0.010 |
Why?
|
| Pregnancy, High-Risk | 1 | 1991 | 121 | 0.010 |
Why?
|
| Hematocrit | 1 | 1991 | 621 | 0.010 |
Why?
|
| Aerosols | 1 | 1992 | 633 | 0.010 |
Why?
|
| Gonadal Steroid Hormones | 1 | 1993 | 705 | 0.010 |
Why?
|
| Mastectomy, Segmental | 1 | 1994 | 964 | 0.000 |
Why?
|
| Kidney Function Tests | 1 | 1991 | 683 | 0.000 |
Why?
|
| Aneuploidy | 1 | 1992 | 578 | 0.000 |
Why?
|
| Mastectomy | 1 | 1997 | 1847 | 0.000 |
Why?
|
| Pregnancy Trimester, Second | 1 | 1991 | 738 | 0.000 |
Why?
|
| Maternal Age | 1 | 1991 | 804 | 0.000 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1992 | 2477 | 0.000 |
Why?
|
| Autoimmune Diseases | 1 | 1999 | 2226 | 0.000 |
Why?
|
| Neck | 1 | 1991 | 733 | 0.000 |
Why?
|
| Probability | 1 | 1991 | 2475 | 0.000 |
Why?
|
| Lymphatic Metastasis | 1 | 1993 | 2887 | 0.000 |
Why?
|
| Menopause | 1 | 1993 | 1659 | 0.000 |
Why?
|
| Receptors, Estrogen | 1 | 1993 | 2242 | 0.000 |
Why?
|
| Kinetics | 1 | 1992 | 6274 | 0.000 |
Why?
|
| HIV Infections | 1 | 2011 | 17533 | 0.000 |
Why?
|
| Gestational Age | 1 | 1992 | 3613 | 0.000 |
Why?
|
| Palliative Care | 1 | 1998 | 3645 | 0.000 |
Why?
|
| Sepsis | 1 | 1996 | 2606 | 0.000 |
Why?
|
| Length of Stay | 1 | 1994 | 6485 | 0.000 |
Why?
|
| Brain | 1 | 2007 | 27178 | 0.000 |
Why?
|